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Attractor Molecular Signatures and Their Applications for Prognostic Biomarkers
Wei-Yi Cheng
This dissertation presents a novel data mining algorithm identifying molecular sig-
natures, called attractor metagenes, from large biological data sets. It also presents a
computational model for combining such signatures to create prognostic biomarkers. Us-
ing the algorithm on multiple cancer data sets, we identified three such gene co-expression
signatures that are present in nearly identical form in different tumor types represent-
ing biomolecular events in cancer, namely mitotic chromosomal instability, mesenchymal
transition, and lymphocyte infiltration. A comprehensive experimental investigation us-
ing mouse xenograft models on the mesenchymal transition attractor metagene showed
that the signature was expressed in the human cancer cells, but not in the mouse stroma.
The attractor metagenes were used to build the winning model of a breast cancer prog-
nosis challenge. When applied on larger data sets from 12 different cancer types from
The Cancer Genome Atlas “Pan-Cancer” project, the algorithm identified additional
pan-cancer molecular signatures, some of which involve methylation sites, microRNA
expression, and protein activity.
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The goal of this thesis is to introduce several molecular signatures that are identified by
a novel data mining algorithm across multiple genome-scale biomedical data sets, which
we called attractor metagenes. These attractor molecular signatures were found in nearly
identical form in multiple data sets of different cancer types, and therefore we hypothezie
that they represent the unifying characteristics in cancer. The “pan-cancer” molecular
signatures provided insights in generating novel hypotheses for cancer biology and helped
build models used to predict clinical phenotypes.
1.1 Background
Cancer is prevailingly viewed as a process of clonal evolution. In 1976, Peter Nowell
proposed that tumor initiation occurs by an induced change in a single, previously normal
cell, making the cell neoplastic and providing it with a selective growth advantage over
adjacent normal cells [1]. This neoplastic proliferation then proceeds, allowing sequential
selection of more aggressive sublines. As evidenced by its pathological manifestations,
cancer is also recognized as many diseases, differing in each patient, which progressively
evolve through interplay with a changing environment. The unique nature of cancer
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demands a more individually-tailored treatment − one that identifies the characteristics
of a tumor and adopts therapy accordingly. Even before the term “personalized medicine”
emerged, oncologists focused on identifying histological or molecular markers in tumor
specimens from individual patients which were associated with prognosis or responses to
a specific treatment.
Ever since the Human Genome Project [2] was completed, the information of individ-
ual genetic, genomic, epigenomic, and proteomic characteristics gradually increased their
influence on medical decisions, practices, and products. Cancer management has also
begun to incorporate information regarding specific genetic defects in a tumor, as well as
the genomic profile of the tumor to improve outcomes. For this purpose, Cancer Genet-
ics and Cancer Genomics have been growing and evolving rapidly as a dynamic area of
research, aiming to discover and develop “biomarkers”−measured characteristics that in-
dicate a biological state or condition, which leads to significant effects on risk or response
to therapy. The advent of microarray technology and, more recently, high-throughput
sequencing technologies, have made it possible to systematically analyze genomic infor-
mation of tumor samples. New tools have also been developed for connecting clinical
phenotypes of a tumor with its genomic profile by model-driven, knowledge-driven, or
data-driven approaches [3].
One of the most interesting tasks that can be accomplished by large-scale data-driven
approaches is the identification of common gene signatures across cancer types. Despite
the fact that many diseases are known to be “cancer,” it has been appreciated that there
exist some unifying capabilities, or “hallmarks,” characterizing all cancers. As proposed
in two seminal papers by Douglas Hanahan and Robert Weinberg [4, 5], the hallmarks of
cancer constitute an organizing principle for rationalizing the complexities of neoplastic
disease, underlaid by genomic instability. Furthermore, it has been recognized that gene
expression signatures resulting from analysis of cancer datasets can serve as surrogates
of cancer phenotypes [6]. Therefore, it is reasonable to hypothesize that computational
analysis of rich biomolecular cancer datasets may reveal signatures that are shared across
2
many cancer types and are associated with specific cancer phenotypes. As data sets
from systematic cancer genomics projects (e.g., The Cancer Genome Atlas [TCGA]) [7],
become publicly available at an increasing rate, integrating analyses from multiple can-
cer types provides a great opportunity for understanding cancer biology and developing
tailored treatment for the disease.
Attempts to identify robust “bioinformatic hallmarks” of cancer have, so far, been
largely unsuccessful. Gene signatures may occasionally be found to exhibit similarities
across multiple cancer types. However, to our knowledge no algorithm has ever produced
a set of nearly identical signatures after independently and separately analyzing datasets
from different cancer types.
1.2 Previous Work on Identifying Cancer-Related Gene
Signatures
Module Networks
There are various ways in which modules of coexpressed genes can be identified from rich
datasets, some of which may be within the context of regulatory network discovery [8].
Such methods identify modules of co-regulated genes and their shared regulation program,
specifing the expression profile of a module’s genes as a function of the expression of
the module’s regulators. It was shown [9] that this higher-level analysis improved both
statistical robustness and biological interpretability.
In [9], the module network approach was applied to a lung cancer data set, which led to
the identification of multiple modules. These modules were enriched for genes associated
with expected functions, such as extracellular inflammation, immunity and extracellular
matrix. Leter in [10], these modules were associated with tumor progression, as the genes
were shown to be expressed during the Epithelial to Mesenchymal Transition (EMT) [10].
While the regulatory module network approach succeeded in identifying oncogenic
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gene modules, the benefit of incorporating regulatory information remains unclear. As the
regulatory and signaling networks are very complex and many interactions are context-
specific, the regulators in the module network do not give us new insight into carcinogen-
esis, as most of them were identified before the introduction of high-throughput methods.
On the other hand, the coexpressed modules are also interpretable and would have been
identified without regulator information. The regulatory information seems to add lim-
ited value to a fully coexpression-based approach.
Coexpression Networks
Weighted Gene Coexpression Network Analysis (WGCNA) is a bottom-up approach
which builds weighted gene network from an adjacency matrix, where the connections
between gene pairs are represented by the power adjacency function [11]. Unlike the reg-
ulatory module network approach, modules are defined solely based on gene expression
patterns, without incorporating any regulatory information. The algorithm uses topolog-
ical overlap dissimilarity as the distance measure for hierarchical clustering, and chooses
a height cutoff on the dendrogram to reach a gene module. The modules are then re-
lated to external information such as clinical phenotypes or Gene Ontology (GO) [12].
Downstream analysis includes refining a module by studying module preservation across
different data sets, investigating intermodular connectivity or incorporating regulatory
information to identify key genes in the modules.
WGCNA has been applied in many studies to identify disease-associated gene modules
or key oncogenes. A study by Horvath et al., comparing module structure in Glioblastoma
and normal tissues, revealed gene ASPM as a molecular target for inhibiting tumor cell
and neural stem cell proliferation [13]. Hu et al. did a cross-species study which compares
the gene membership of networks in human breast cancer data sets and mouse model data
sets. Their study identified a conserved network which can be used to predict distant
metastasis-free survival [14]. Applying WGCNA on data sets from 33 types of cancer by
Zhang et al. also identified a common network which contains many genes with genome
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stability maintenance functions [15].
The coexpression network analysis is indeed a powerful tool to identify gene modules
across data sets of different cancer types. However, the key genes or shared networks
identified by multi-cancer analysis do not result in a well-defined signature, especially
one that can be used as a “proxy” to represent the underlying biological mechanism. The
genes connected in the same network are necessarily highly coexpressed together, but
may be linked through other genes. To identify the “core” of the coexpression requires
an iterative approach to refine the composition of gene sets.
Clustering
Cluster analysis is one of the most fundamental data mining techniques. It classifies a
selected set of genes into subsets, each of which contains mutually related genes. As
moving on the hierarchy, hierarchical clustering iteratively updates cluster memberships
by merging two closest clusters (bottom-up approach), or splitting a cluster into two most
distinct clusters (top-down approach). K-means clustering presets K centers in the data
and iteratively assigns each gene to the closest center, defining a new center, which leads
to new assignments of centers for each gene. An alternative to defining the center as mean
in K-means clustering is to use median, or K-medoids. The most common realisation of
such clustering is the Partitioning Around Medoids (PAM) algorithm [16].
Parker et al. applied the PAM algorithm to identify a 50-gene subtype predictor
(PAM50) and 4 intrinsic subtypes. The correlation coefficients between a sample’s 50-
gene profile and the 4 subtypes can be used to produce a risk of relapse (ROR) score to
predict the prognosis [17]. Clustering methods have been used to classify samples into
cancer subtypes. Phillips et al. performed K-means clustering on a data set which con-
tains samples of grade III and IV glioma and identified three subtypes which correlate
with survival. Using a centroid-based clustering method, they also defined the signature
genes for each subtype [18]. Verhaak et al. later analyzed the TCGA glioblastoma data
set using the hierarchical clustering on the samples, and identified the signature genes
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using the same centroid-based method. The TCGA Research Network applied SigClust,
which integrates clustering with significance evaluation, semi-supervised hierarchical clus-
tering using gene signatures of intrinsic subtypes, and PAM50 on the TCGA breast gene
expression data set. High concordance was observed with all three analyses [19].
While cluster analysis is widely used, gene signatures produced by such analysis do not
lead to direct application of predictive modeling. Most studies identified 5 to 10 clusters
of samples defined as “subtypes.” These subtypes, however, give only general guidelines
of the genomic profile of the tumor. This results in exceptions or more sub-rules when
making treatment decisions based on subtypes, even the replacement by other markers.
For example, in breast cancer, subtyping by immunohistochemistry and histological grade
outperformed breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy
response [20]. A majority of the panel at the St. Gallen Consensus Conference still
pled against multi-gene expression array profiling being required for subtype definition.
About half of the panel opted to use a clinicpathologic definition of estrogen receptor,
progesterone receptor, HER2 and Ki-67 for subtype definition [21].
Non-negative Matrix Factorization (NMF)
NMF [22] is one of the most powerful computational approaches for gene signature iden-
tification and subtyping. Given a gene expression matrix A with m rows as genes and n
columns as samples, NMF factorizes V into two matrices: a matrix W with m genes and
k “metagenes,” which are defined as the weighted sum of the m genes, where weights are
non-negative; and a matrix H with k metagenes and n samples. Given a factorization
A ∼ WH, the matrix H can be used to define k clusters of samples, where a sample is
placed into the i-th cluster if its i-th metagene has the highest expression value among
other metagenes. In practice, it is combined with consensus clustering [23] to determine
the number of k, resulting in objective determination of the number of subtypes.
Collisson et al. applied NMF on data sets from pancreatic ductal adenocarcinoma
(PDA) and defined three PDA subtypes which are associated with clinical outcome [24].
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TCGA Research Network applies NMF consensus clustering on TCGA ovarian gene ex-
pression data set and identifies 4 subtypes. The 193 signature genes were also used to
predict overall survival [25]. NMF consensus clustering was also applied on the TCGA
breast cancer microRNA expression data set, which led to the identification of 7 subtypes
[19].
NMF suffers from the fact that the metagenes defined by factorization do not lead to
signatures which can be re-used for predictive modeling or serve as proxies of underlying
biological mechanism. NMF defines gene sets which may contain genes that are less
correlated with others. Also, in NMF, it is difficult for the user to refine the members of
a metagene, given that the approach does not provide a measurement for the importance
of the genes in a metagene. To address these drawbacks, an algorithm which clearly
defines the importance of each gene in the module is needed.
Identifying Gene Signatures Across Tumor Types
As the number of cancer data sets increases in an exponential way, more and more studies
have began to focus on interesting common findings across tumor types. TCGA research
network launched the Pan-Cancer project in October 2012 because through their previous
endeavors [26, 25, 19, 27], researchers identified several similarities among tumor types
across different organs. For example, TP53 mutations were found as drivers in high-grade
serous ovarian, serous endometrial, and basal-like breast carcinomas. All of which share
a global transcriptional signature involving the activation of similar oncogenic pathways.
The ERBB2 mutation and/or amplification in subsets of glioblastoma, gastric, serous
endometrial, bladder and lung cancers suggests possible responsiveness to HER2-targeted
therapy used in breast cancer. These common molecular traits are helpful to making
biological discovery, as well as cancer management [28].
However, there are still no precisely defined pan-cancer gene expression signatures
identified using these data sets. We argue that it is because the current computational
tools to identify gene signatures, as mentioned in the previous section, are not designed
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for such applications. The main objective addressed by techniques such as NMF is to
reduce dimensionality by identifying a number of metagenes jointly representing the gene
expression dataset as accurately as possible, in lieu of the whole set of individual genes.
Each metagene in NMF is defined as a positive linear combination of the individual
genes, so that its expression level is an accordingly weighted average of the expression
levels of the individual genes. The identity of each resulting metagene is influenced by
the presence of other metagenes within the objective of overall dimensionality reduction
achieved by joint optimization.
By contrast, if the aim is exclusively to identify metagenes as surrogates of biomolec-
ular events, then a fully unconstrained algorithm should be devised, without any effort
to achieve dimensionality reduction, classification, mutual exclusivity, orthogonality, reg-
ulatory interaction inference, etc.
Based on this idea, and to address problems of the commonly used gene signature-
identification algorithms mentioned above, we developed a computational method for
generating signatures using an iterative process that converges to one of several precise
“attractors,” defining signatures representing biomolecular events. The method is unsu-
pervised, easy to parallelize, and most importantly, it identifies gene signatures in nearly
identical form in independent data sets from multiple cancer types. While methods such
as coexpression networks require refining modules using multiple data sets to identify key
genes, our iterative algorithm gives importance to the gene members in each attractor,
thereby highlighting which genes will be important in another data set. The produced
gene signatures can also be directly used as features in predictive modeling. The iden-
tified pan-cancer signatures are also found to be associated with clinical phenotypes.
In this dissertation, we will present the algorithm to generate the attractors, interest-
ing cancer-associated attractors that we found present in multiple cancer types, and an
example of applying the pan-cancer gene expression signatures when predicting breast
cancer prognosis.
We consider the pan-cancer signatures represent the “bioinformatic hallmarks” of
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cancer. We believe that each signature represents an important biomolecular event in
cancer, and can be used as important quantitative assays for cancer management and
treatment decisions.
1.3 Contributions of the Thesis
Chapter 2 introduces algorithms to iteratively identify attractor metagenes, to generate
consensus gene signatures from multiple data sets, and to evaluate the significance of
the attractors. The choice of parameters in the algorithm and its effect on the results is
discussed. The chapter also will compare the results generated by the proposed algorithm
with other unsupervised algorithms. Finally, the algorithm’s computational complexity
and implementation issues are discussed.
Chapter 3 presents the 18 pan-cancer signatures identified from data sets in the TCGA
Pan-Cancer Project. Hypotheses of the functional role of some signatures are made. The
chapter also shows some interesting associations among pan-cancer signatures and their
implications on cancer biology.
Chapter 4 shows our further investigation on one of the most prominent pan-cancer
signatures − the mesenchymal transition (MES) signature. We have linked the expression
of the signature to tumor stage in multiple cancer types, and the time to recurrence
in glioblastoma. In a glioma data set, we also found the signature to be associated
with a biomarker for stemness, which is consistent with previous observation that cancer
cells which underwent epithelial to mesenchymal (EMT) transition showed stem cell-
like properties. The similarities and differences between the pan-cancer MES signature
and other mesenchymal subtype gene signatures is also discussed. Finally a xenograft
experiment to investigate the source of the signature is presented.
Chapter 5 presents an example of building a cancer prognosis model using these pan-
cancer signatures. Our work from the Sage Bionetworks-DREAM Breast Cancer Prog-
nosis Challenge (BCC) will be highlighted. We hypothesized that each of the pan-cancer
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signatures represented important biomolecular events of cancer, and would therefore be
associated with phenotypes in multiple cancer types. In this challenge, We identified that
each pan-cancer signature is associated with breast cancer survival under a specific con-
dition. By modifying the features according to its corresponding condition, the prognosis
model won “Best Performer” at the BCC.
Finally, Chapter 6 concludes this thesis, proposing several directions for extending




An attractor metagene is a weighted average of genes, which defines a molecular signa-
ture of a highly coexpressed gene set. An attractor metagene is identified through an
unsupervised, iterative computational procedure that converges to an exact weighted av-
erage. The power of this approach emerges when one compares the attractors identified
in data sets from multiple cancer types. Several of the molecular signatures defined by
attractor metagenes were found in nearly identical form regardless of cancer type, thus
representing the “pan-cancer” biomolecular events. This chapter describes the iterative
algorithm which was used to identify attractor metagenes, the clustering algorithm to
create the consensus pan-cancer signatures from multiple data sets, and the procedure
used to evaluate the significance of the identified pan-cancer signatures. We will also dis-
cuss the effects of the parameters used in the algorithm, implementation complexity, and
compare the difference between this methodology and other well-established algorithms
in order to identify gene expression signatures.
An R (http://cran.us.r-project.org/) package of the attractor-finding algorithm
is available on GitHub: https://github.com/weiyi-bitw/cafr.
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2.1 Derivation of an Attractor Metagene
Given a nonnegative measure J of pairwise association between the genes Gi and Gj in a
data set, we define an attractor metagene M to be a linear combination of the expression
values of individual genes, or M =
∑
iwiGi, with weights wi = J(Gi,M). The association
measure J is assumed to have minimum possible value 0 and maximum possible value 1,
the same being true for the weights. The weights are also assumed to be scale-invariant,
therefore it is not necessary for them to be normalized so that they add to 1. In practice,
we chose the weight function J to be the normalized mutual information (MI) [29] to
the power of α, or J(Gi,M) = (MI(Gi,M))
α. Appendix A gives details about the
normalized MI and how to estimate MI between two continuous variables. However, MI
does not indicate if the two variables’ correlation is positive or negative. Because our
goal is to generate strongly coexpression gene signatures, we disregard the genes with
negative association with the metagene, as they will become another metagene if we use
a different seed. The weight function becomes:
J(Gi,M) =
 (MI(Gi,M))
α if cor(Gi,M) ≥ 0
0 if cor(Gi,M) < 0
For a gene expression data set with around 25,000 genes being profiled, an empirical
choice of α is 5. See Section 2.5 for discussions about the choice of the measure J and
the choice of α.
According to this definition, the genes with the highest weights in an attractor meta-
gene will have the highest association with the metagene (by implication, tending to be
highly associated among themselves) and will often represent a biomolecular event re-
flected by the coexpression of these top genes. This can happen, e.g. when a biological
mechanism is activated, or when a copy number variation (CNV), such as an amplicon,
is present in some of the samples included in the expression matrix. In the following of
the thesis, we use the term “attractor” for simplicity to refer to an attractor metagene,
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and the term “top genes” to refer to the genes with the highest weights in the attractor.
The definition of an attractor metagene can readily be generalized to include features
other than gene expression, such as methylation values. It can also be used in datasets
characterized by any type of feature vectors (not necessarily genes), having applications
in other disciplines, such as social and economic sciences as well.
The computational problem of identifying attractors given an expression matrix can
be addressed heuristically using a simple iterative process: Starting from a particular
seed (or “attractee”) metagene M , a new metagene M ′ is defined in which the weights
are w′i = J(Gi,M). The same process is then repeated in the next iteration, resulting in
a new set of weights. That is, given the metagene Mk at iteration k, a new metagene
Mk+1 at iteration (k+ 1) is defined by weights wk+1i = J(Gi,M
k). In all gene expression
datasets that we tried, we found that this process converges to a limited number of stable
attractors. Each attractor is defined by a precise set of weights which are reached with
high accuracy, typically within 20 or 30 iterations. The pseudo-code for the iterative
process is given in Algorithm 2.1.
Figure 2.1 demonstrates the convergence process in The Cancer Genome Atlas (http:
//cancergenome.nih.gov/) lung squamous cell carcinoma (LUSC) mRNA sequencing
(RNASeq) data set. The seed metagene was set as the collagen type XI alpha 1 (COL11A1 )
single gene, whose weight vector was defined by wCOL11A1 = 1, otherwise wGi = 0. In
each iteration, the top 15 genes of the attractor are shown. Within 10 iterations, the at-
tractor converges to a stable ranking of genes led by THBS2, COL5A2, BGN, COL3A1,
COL5A2, etc. From iteration 10 to iteration 20, not only do the rankings of the genes
do not change, but the MI between each gene and the attractor metagene also converges
to a precise number. For more details regarding the data set source, access to the data,
and the preprocessing, please refer to Appendix B.
This algorithmic behavior with precise convergence properties is not surprising, if a
metagene represents coexpressed genes, then the next iteration will naturally “attract”
other similarly coexpressed genes, and so forth, until there are no other genes more asso-
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Algorithm 2.1 Find an Attractor M From a Seed Metagene Mseed
Require: Expression values of genes G1, G2, . . .Gm
Require: Expression values of the seed metagene Mseed and its weight vector Wseed =
(w0, w1, . . . , wm)
Require:  : Threshold for convergence





while d >  and k < K do
W ′ ← (J(G0,M), J(G1,M), . . . J(Gm,M))
d← ‖w′ − w‖
W ← W ′
M ←∑iwiGi
k ← k + 1
end while
if k ≥ kmax then




ciated with the top genes than those genes themselves. Furthermore, the set of the few
genes with the highest weight are likely to represent the core of the underlying biomolec-
ular event. In support of this concept, the association of any of the top-ranked individual
genes with the attractor is consistently and significantly higher than the pairwise asso-
ciation between any of these genes, suggesting that the set of these top genes jointly
comprise a proxy representing a biomolecular event better than each of the individual
genes would.
To find all attractors in a given data set, a reasonable implementation of an “exhaus-
tive” search of attractors is to start from each individual gene as a seed (“attractee”),
assigning a weight of 1 to that gene, and 0 to all the other genes. Each gene participating
in a particular coexpression event will then lead to the same attractor when used as an
attractee. The computational implementation of the algorithm is described in Algorithm
2.2.
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Figure 2.1: Convergence process of an attractor. Each ranked list shows the top 15 genes and
their MI with the metagene at that iteration. The seed is the single gene of COL11A1.
The identified attractors can be ranked in various ways. We defined the “strength
of an attractor” as the MI between the nth top gene of the attractor and the attractor
metagene. Indeed, if this measure is high, it implies that at least the top n genes of
the attractor are strongly coexpressed. We selected n = 10 as a reasonable choice,
not too large, but sufficiently so to represent a real, complex biological phenomenon of
coexpression with at least ten genes.
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Algorithm 2.2 Find All Attractors M in a Data Set D
Require: Expression values of genes G1, G2, . . .Gm in D
Require:  : Threshold for convergence
Require: kmax : Maximum number of iteration
Require: findAttractor(D,Mseed, , kmax) : The function to find an attractor given a
seed metagene Mseed, as described in Algorithm 2.1
M← ∅
for i← 1 to m do
Mseed ← Gi
M ← findAttractor(D,Mseed, , kmax)





2.2 Derivation of a Genomically Co-localized Attrac-
tor Metagene
As mentioned previously, the coexpression of the top genes in an attractor sometimes
captures an amplicon’s involvement in a CNV event. Because CNVs frequently contribute
to tumorigenesis [30], we have modified the algorithm to detect strongly coexpressed genes
in a genomically adjacent region which form a genomically co-localized attractor.
To identify genomically co-localized attractors, we use the same algorithm as described
above, but for each seed gene we restrict the set of candidate attractor genes to only
include those in the local genomic neighborhood of the gene. We also optimize the
exponent α so that the strength of the attractor is maximized. Specifically, we sort the
genes in each chromosome in terms of their genomic location and we only consider the
genes within a window of size h (i.e., with h/2 genes on each side of the seed gene). For
gene expression data sets, h = 50 is a practical choice, but 30 or 70 will create similar
results. We further optimize the choice of the exponent for each seed by allowing it to
range from 1.0 to 6.0, with a step size of 0.5, and selecting the attractor with the highest
strength.
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Because the set of allowed genes is different for each seed, the attractors will be
different from each other, but “neighboring” attractors will usually be very similar to
each other. Therefore, following exhaustive attractor finding from each seed gene in a
chromosome, we apply a filtering algorithm to only select the highest-strength attractor in
each local genomic region, as follows: For each attractor, we rank all the genes in terms
of their MI with the corresponding attractor and we define the range of the attractor
to be the chromosomal range of its top 15 genes. If there is any other attractor with
overlapping range and higher strength, then the former attractor is filtered out. The
strength of a genomically co-localized attractor is practically defined as the MI between
the fifth top gene of the attractor and the attractor metagene. This filtering is done in
parallel, so that the elimination of attractors occurs simultaneously.
2.3 Derivation of Consensus Attractor Signatures
An “attractor signature” is defined as a set of the top genes of the attractor, that is, a gene
set that includes only the genes that are significantly associated with the attractor. There
are many advantages of using such precisely defined gene sets instead of the weighted
average of all genes. For example, after the non-correlated genes were eliminated, the
metagene (now defined as the simple average of the top genes) represents more sharply
the biomolecular events reflected by the coexpression. This well-defined membership after
the convergence also allows the definition of similarities of the attractors identified across
multiple data sets, or the overlap between an attractor and known gene sets.
One of the advantageous features of the iterative attractor-finding algorithm is not
only its convergence to the core of underlying biological coexpression mechanisms, but
also its ability to lead to the discovery of multiple, nearly identical signatures after in-
dependently analyzing data sets from different cancer types. This provides an additional
opportunity to combine the powers of a large number of rich data sets in order to focus,
at an even sharper level, on the core genes of the underlying mechanism.
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After applying the attractor finding algorithm in each data set, in order to create a
consensus attractor signature out of similar attractors, we filtered out any attractors that
resulted from less than three attractee (seed) genes then ranked the attractors according
to their strengths. A hierarchical clustering algorithm [31] was performed to objectively
cluster similar attractors from different data sets. In the following, Ai denotes an attractor
cluster which contains several attractors, from one to as many as the number of data sets
analyzed. The similarity measure S between two attractor clusters Ai,Aj are defined as
follows:
(1) S(Mx,i,My,j) =









Where the function Cn(Mx,i,My,j) returns the number of overlapping genes between the
top n genes of two attractors Mx,i and My,j. An empirical choice for n is 50 for gene
expression attractors, given that for most gene expression attractors the top 50 genes
remains high MI with the attractor metagene. We used n = 15 for genomically co-
localized attractor since it’s the size of the gene set defined as the range of such attractors.
If two attractors are from the same data set, their similarity measure is defined as 0 even
if they may occasionally have overlapping genes.
Starting from the two attractors with the highest similarity measure, the clustering
algorithm proceeds until there is no attractor cluster pair that can be further clustered
together. If two attractor clusters both contain attractors from the same data sets, they
will not be further clustered into one cluster. Figure 2.2 shows the results of attractor
clusters after applying the clustering algorithm on the attractors found in six independent
cancer data sets of three cancer types (see Appendix B for details on the data sets). Due
to limited space, we can only show the top 5 genes of each attractor. In fact, there are
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8 genes in the “Mesenchymal Transition attractor” and 13 genes in the “Mitotic CIN
attractor” which appear as the top 50 genes of the attractor. Details of this table are
available in the supplementary Table S1 in [32].
A consensus attractor signature is created from an attractor cluster by ranking the
genes in terms of their average MI among the attractors in that cluster and by selecting
the top genes in the consensus ranking to be the consensus attractor signature.
2.4 Evaluating the Significance of an Attractor
Signature
The significance of the identified attractors or attractor signatures an be evaluated from
several perspectives. For example, the strength of an attractor, or the number of genes
in the attractor with MI higher than some threshold (e.g. 0.5), can be used as figures
of merit for evaluating the significance of finding so many strongly-associated genes in a
data set. A non-parametric approach such as bootstrapping or permutation of the data
set is used to generate an empirical distribution and to evaluate the P value.
On the other hand, to evaluate the significance of the consistency of the attractors
identified across data sets, we used the number of genes which appear in the top n genes
in all data sets as a figure of merit after clustering the attractors.
Given sets of attractorsM1,M2, . . . ,Mk created from data sets D1,D2, . . . ,Dk, after
clustering the attractors, we obtain attractor clusters A1,A2, . . . ,At. Without loss of
generality, assume there are m genes in A that appear in the top n genes in all k data sets.
We randomly generate ‖M1‖, ‖M2‖, . . . , ‖Mk‖ random gene sets of size n respectively in
each data set and apply the same clustering algorithm to create attractor clusters based
on random gene selection A′1,A′2, . . . ,A′t′ . Then we are able to count the maximum
number of genes among all A′’s that appear in all k data sets. We repeat this random
process millions of times and obtain the empirical distribution of the maximum number
of genes common in all k data sets. This empirical distribution is used to generate the P
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value of the consistency of the attractor signatures.
We used six data sets of three different cancer types (see Appendix B) (n = 50, k = 6)
to evaluate the significance of two of the pan-cancer signatures (MES, mitotic CIN). We
repeated the above random process − generating the maximum number of genes common
in all 6 data sets − ten million times. In these ten million experiments, it never occurred
that more than one gene was common in all 6 datasets. Therefore, the corresponding P
value for both the mesenchymal transition metagene as well as the mitotic CIN metagene
is less than 10−7, and is in fact much lower than that given the large number (8 and 13
respectively) of the common genes. More details about this experiment are available in
[32].
This random process constitutes a conservative way of evaluating consistency in the
sense that for each random experiment we only record the maximum number of common
genes in the gene set cluster, and we created random gene sets using only the common
genes in the six datasets. On the other hand, the attractor cluster may not have the
highest number of genes, and every attractor was generated using all the genes in each
data set, not restricted to the overlapping genes. However, even though the estimated
significance is conservative, in practice we still find significance in all pan-cancer attractor
signatures that we identified and discussed in the next chapter.
2.5 Choice of Parameters in the Iterative Algorithm
The weight function determines the convergence of the iterative attractor-finding algo-
rithm. An interesting coincidence was observed that there are similarities between weight
function to define an attractor metagene with the power adjacency function used to con-
struct Weighted Gene Co-expression Networks (WGCNA): both the weight function and
the power adjacency function are defined as the power function of the association measure.
The power adjacency function of WGCNA is set to the 6-th power of Pearson correlation,
while the weight function is set to default to the 5-th power of MI. Although the WGCNA
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was published in 2005, the development of the attractor metagene approach was not influ-
enced by the coexpression network approach. The attractors provide a naturally defined
signatures represented by the top genes which can be used to derive features to build
predictive models directly, but WGCNA only focuses on the significance of topological
similarities without identifying the core signature to the coexpression. In the following,
We will discuss the effects of using different parameters in the weight function.
The exponent α
Changing α directly affects the number of converged attractors found in the data set. At
one extreme, if α is sufficiently large then each of the seeds will create its own single-gene
attractor because all other genes will always have near-zero weights. In that case, the
total number of attractors will be equal to the number of genes. At the other extreme,
if α is zero, then all weights will remain equal to each other, representing the average of
all genes, so there will only be one attractor. The higher the value of α, the “sharper”
(more focused on its top gene) each attractor will be and the higher the total number of
attractors will be. As the value of α is gradually decreased, the attractor from a particular
seed will transform itself, occasionally in a discontinuous manner, thus providing insight
into potential related biological mechanisms.
Figure 2.3 illustrated the relationships between the choice of α and the converged at-
tractors, using CENPA as seed in the TCGA ovarian gene expression microarray data set.
Based on the strength of converged attractors, we can roughly categorize the attractors
obtained by different α into three situations:
• α too low: The converged attractor contains top genes of less correlated genes. The
converged attractor is simply the average of these genes.
• Good α: The top genes of the converged attractor are highly associated with the
attractor metagene (usually greater than 0.5). The top genes are highly associated
among themselves. The attractor defines a meaningful, strongly coexpressed gene
set.
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• α too high: The seed gene retain high weight throughout the iterative process, while
the other genes have nearly no weight in the metagene. The ranking of the genes
is dominated by the seed.
The three situations can be clearly distinguished by the discontinuous point of the
strength. This indicates the attractor “jumps” from one state of convergence into another.
Our choice of α = 5 is determined by observing such plots for several data sets. We found
that in most cases α = 5 leads to a nicely converged attractor.
The association measure
Using different association measure will only result in a slight difference in gene rank-
ings of the converged attractors. However, when a linear association measures, such as
Pearson product-moment correlation coefficient is used, a higher exponent is required to
create similar attractors to those created using MI. Note that WGCNA by default uses
6-th power of Pearson correlation coefficient to construct adjacency matrix. We would
recommend using the 10-th power of Pearson correlation coefficient when applying the
algorithm.
A rank-based correlation measure can also be used, such as the Spearman’s correlation
coefficient. When using the rank-based association measure, one would observe a perfect
convergence given that two correlation coefficients will be identical as long as the ranks
between two are the same iterations and did not change. However, using a rank-based
correlation measure is more costly in terms of time complexity.
The weight function J
The weight function does not need to be a power function of the association measure.
An alternative to the power function can be a sigmoid function with varying steepness,
but we found that the consistency of the resulting attractors was worse in that case.
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2.6 Comparison with Other Unsupervised Algorithms
The scope of the algorithm identifying attractor metagenes is different from that of other
unsupervised methods, which are usually aimed at identifying subtypes, performing di-
mension reduction, or identifying mutually exclusive clusters. Nevertheless, it is inter-
esting to find to what extent other algorithms can produce multiple cancer signatures
each of which appears in nearly identical forms across different cancer types. We applied
three widely used methods: k-means clustering, principal component analysis (PCA),
and hierarchical clustering on the six cancer datasets used in previous section (Appendix
B). In all cases, we listed the top fifty genes in each cluster or PC and applied the same
clustering algorithm as in Section 2.3 to find common genes among them and to group
them together. The choice of parameters and the results are as follows:
K-means clustering
We used the kmeans function provided in R. The number of clusters k is the one at
which the reduction of within-group sum of squares (SS) decreases most significantly.
This produces the “elbow” of the curve, depicting k versus within-group SS. Using the
top 50 genes in each cluster, as ranked by their correlation with the center of the cluster,
we found no significant overlap within common clusters in all data sets, as the most
common gene only appears in four of the six data sets. Details regarding the found
clusters in six data sets and the k versus within-group SS are available in Text S2 and
Table S5 in [32].
PCA
PCA places the genes in the data set into principle components (PCs) − which are
essentially metagenes − according to the co-variances between gene pairs. We used the
prcomp function provided in R. After obtaining the PCs, we created the gene sets using
the top 50 genes with the highest absolute values of the loadings in the first ten PCs for
each data set. We found two gene set clusters, each of which contains one gene common
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in six data sets. The consistency is not as high as the attractor clusters, as two attractor
clusters contain 8 and 13 genes common in all six data sets. The top genes in the top ten
PCs in six data sets are available in Table S6 in [32].
Hierarchical clustering
We used the hclust function provided in R with the average linkage and the Pearson
correlation coefficient as the similarity metric. We cut the tree generated by the algorithm
at 200 clusters. With this choice, after eliminating small clusters that have less than ten
genes, we got 50 to 100 remaining clusters in each dataset, which is approximately the
same number of attractors that we got from each data set. Other choices close to this
number gave similar results. We found one gene set cluster with five genes common in
all six data sets. We also found several clusters similar to the attractor clusters, but
their consistency was not as high. The top genes in the top ten PCs in six data sets are
available in Table S7 in [32].
We also compared qualitatively the attractor-finding algorithm with two gene expres-
sion signature-finding algorithms: the Iterative Signature Algorithm (ISA) [33] and the
Independent Component Analysis (ICA) [34].
ISA
The Signature Algorithm by Ihmels et al. [35] generates a gene signature based on
the changes in expression levels within specific “experiment signatures.” The algorithm
receives a set of genes as input, and identifies genes that are consistently differentially
expressed across several experimental conditions compared with the average expression
across all conditions. The authors revised the algorithm into the Iterative Signature
Algorithm (ISA) [33], which iteratively performs two steps: (1) identifies “conditions” in
which the average differential expression of the genes exceeds some threshold, and (2)
identifies “genes” that are highly differentially expressed in the conditions identified in
the previous step. Through the iterations, the algorithm keeps modifying the conditions
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and genes according to the previous step. The ISA involves the modification of both
genes and conditions (or in the case of data sets containing cancer patients, the samples).
On the other hand, the iterative process in the attractor finding algorithm does not
involve the selection of subsets of samples, and therefore does not rely on the simultaneous
differential expression of genes, but on the overall association between genes across all
samples in the data set. As a result, the outputs of the attractor finding algorithm are
signatures which represent only the weighted average of genes, while the output of the
ISA is a gene module which includes a set of genes and several specific samples. In
that sense, the ISA is closer to a bi-clustering algorithm. The important feature of the
attractor algorithm (which also makes it simpler) is that it has nothing to do with the
concept of “subtypes” of samples. It deals exclusively with the rows (genes) of the gene
expression matrix, without considering the columns (samples) in any way. We found that
this simpler method identifies remarkably similar signatures across cancer types, which is
why we think of them as representing important biomolecular events of cancer in general.
ICA
Independent Component Analysis (ICA) [34] decomposes a mixture of signals into addi-
tive subcomponents, under the assumption that each subcomponent is non-Gaussian and
is statistically independent from other subcomponents. ICA identifies multiple sources
of signals in parallel, while maximizing the joint entropy of the signals, or maximizing
the likelihood estimation. It is possible to consider a gene expression matrix as a mix-
ture of metagenes, which can be decomposed by ICA. However, the gene expression data
sets of cancer do not necessarily satisfy the assumptions made by ICA – that the source
signals are statistically independent to each other, and that the distribution of values in
each source signal is non-Gaussian. The attractor-finding algorithm does not make any
assumptions on the distribution of the expression values of an attractor metagene, nor
does it assume the independence between the expression values of attractor metagenes.
In fact, there exist examples when two attractor metagenes found in the same data set
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show correlations in their expression values, as, e.g., is the case with the MES and END
attractor metagenes, which will be further discussed in Section 3.6. The association be-
tween attractor signatures may be useful by shedding light on the interactions between
the underlying biological events. For example in the case of the “invasive” MES and
the “antiangiogenic” END metagenes, their correlation is reminiscent of the observed in-
creased invasiveness of tumors treated with antiangiogenic therapy and it is an interesting
topic of future research to determine if this is related to the two metagenes.
2.7 Implementation Complexity
The time complexity of finding all attractors in a data set is O(nm2), where m is the num-
ber of genes and n is the number of samples in the data set. This is very costly compared
with other unsupervised algorithms which generate gene clusters or metagenes. However,
as shown in the previous section, the attractor signatures have significant consistency
across multiple cancer types which would not be revealed by other unsupervised data
mining algorithms. In our implementation, there are several aspects we used to reduce
the time complexity:
Parallelization
Unlike hierarchical clustering, an attractor can be determined by the seed gene in O(nm).
This makes it perfect for parallelization. One can segregate all the genes in the data set
into b blocks, and assign each block to a worker. This can reach a maximum speedup





When we obtain an attractor using a seed gene, it is reasonable to assume that the top
genes who have high MI with the attractor metagene also converge to the same attractor
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when used as seeds. Therefore, we can remove the top genes in an attractor from the
seed list and reduce the number of seeds to be run in an exhaustive search. A practical
choice is to remove all the top genes with MI higher than 0.5 with the attractor metagene.
This will not reduce the worst-case complexity, but in practice, it generally reduces the
running time of an exhaustive search by 10% to 20%.
Our implementation of the attractor-finding algorithm in R calls external C function
for calculating MI for speed consideration. When executed on an 160-core Sun Grid
Engine (SGE) cluster, provided by Amazon Elastic Compute Cloud (EC2) service, the
program takes about 4 hours to obtain all attractors in a gene expression data set with
25,000 genes and 300 samples.
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Figure 2.2: Top 5 attractor clusters found in six independent cancer data sets of three cancer
types. Each block separated by an empty row represents an attractor cluster. The attractor
clusters are ranked according to the minimum strength among the six attractors in the cluster.
The last row in each attractor cluster shows the most common genes and in how many data
sets the genes appear as the top 50 genes of the attractor.
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Figure 2.3: Relationships between exponent α and the strength of the converged attractor,




Applying the iterative algorithm described in Chapter 2 on data sets from the TCGA
Pan-Cancer Project of 12 cancer types led to 18 pan-cancer attractor signatures, includ-
ing seven mRNA signatures, three DNA methylation signatures, three microRNA sig-
natures, two protein signatures, and three additional genomically co-localized molecular
signatures. Through gene set enrichment analysis (GSEA), using the molecular signa-
ture database (MSigDB) [36, 37], we hypothesized possible biological interpretations of
some of the signatures: the mesenchymal transition (MES) signature is associated with
tumor invasiveness; the mitotic chromosomal instability (CIN) signature is associated
with tumor grade and genomic instability; the lymphocyte-specific (LYM), M+ and M−
signatures, whose expressions are highly correlated, represent the infiltration of possi-
bly a specific T-lymphocytes in a tumor; the Endothelial (END) signature is associated
with angiogenesis. Other signatures were also found to be prominent in multiple can-
cer types. The biological events underlying the coexpression patterns, however, require
further investigation.
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3.1 TCGA Pan-Cancer Project
The Cancer Genome Atlas (TCGA) is one of the largest systematic cancer genome
projects that applies emerging technologies to the analysis of multiple tumor types. Since
its launch in 2005, the TCGA Research Network has profiled and analyzed large numbers
of human tissues. The Pan-Cancer Project [28] aims to discover the possible extension
of therapies in one cancer type to others with similar genomic profiles by systematically
standardizing and analyzing genomic data sets across cancer types in order to identify
molecular aberrations and their functional roles in multiple cancer types. These coherent
biomolecular data sets from the first 12 tumor types profiled by TCGA are also made
available through the Sage Synapse (https://www.synapse.org/) − a computational
platform which provides an opportunity for our data mining approach to computationally
discover and define, with high accuracy, the common patterns representing the unifying
characteristics, or “hallmarks” [5, 4], of multiple cancers types.
Samples of the 12 tumor types in TCGA Pan-Cancer project were profiled by 6 dif-
ferent genomic, epigenomic, transcriptional, and proteomic platforms. The platforms
include Reverse-phase protein analysis (RPPA) measuring protein and phosphoprotein
abundance, microarrays measuring DNA methylation at CpG islands, copy number varia-
tions (CNVs) and gene expression, whole-exome sequencing to determine single-nucleotide
and structural variants (mutation), and sequencing of microRNAs (miRNASeq) and RNA
(RNASeq) measuring their expression. As stated in Chapter 2, the definition of an attrac-
tor metagene can be generalized to include numeric features other than gene expression.
Among these data sets, the mutation information is not applicable for the concept of
attractors because it is unclear how one can generate a “meta-feature” out of the cate-
gorical mutation information. Furthermore, the attractors found in the CNV data sets
are similar to the genomically co-localized attractors found using gene expression data.
Because one of the meaningful biological phenotypes of CNVs is the change in gene ex-
pression [38], we chose to report the genomically co-localized attractors instead of CNV
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attractors.
The following table gives the acronym for each tumor type:
Acronym Cancer type
BLCA Bladder Urothelial Carcinoma
BRCA Breast Invasive Carcinoma
COAD Colon Adenocarcinoma
GBM Glioblastoma Multiforme
HNSC Head and Neck Squamous Cell Carcinoma
KIRC Kidney Renal Clear Cell Carcinoma
LAML Acute Myeloid Leukemia
LUAD Lung Adenocarcinoma
LUSC Lung Squamous Cell Carcinoma
OV Ovarian Serous Cystadenocarcinoma
READ Rectum Adenocarcinoma
UCEC Uterine Corpus Endometrial Carcinoma
3.2 18 Pan-Cancer Molecular Signatures
After normalization, we applied the unsupervized attractor-finding algorithm on the
RNASeq, miRNASeq, DNA methylation and the RPPA data sets of each cancer type
independently. After identifying the attractors in each data set, we applied the attractor
clustering algorithm (as described in Section 2.3) to create consensus RNASeq, miR-
NASeq, DNA methylation, and RPPA attractor signatures across cancer types. We set
the criterion to call an attractor “pan-cancer” if we found it appeared in at least 6 of
the 12 cancer types. While an attractor might not be found in some data sets due to
quality or size of those data sets, an attractor showing consistent coexpression in at least
6 cancer types is already a significant phenomenon, as shown in Section 2.4.
Because an attractor signature is defined by a vector of consensus weights of thousands
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of genes, in practice, we define an “attractor feature” to be the average values of its top
n molecular featrures − genes, methylation sites, proteins, or microRNAs − where n is
determined by molecular types: n = 10 for gene expression (RNASeq) and DNA methy-
lation attractors; n = 3 for protein and miRNA attractors. The attractor features are
used as proxies, indicating the expression levels of the corresponding attractor signatures.
We generate scatter plots, survival curves, and build predictive models based on these
attractor features, as they represent the core of the coexpression patterns shared across
cancer types. For functional analysis, or GSEA, we define the “members” of a signature
to be the molecular features with consensus MI greater than 0.5. For details regarding
data pre-processing, data normalization, and parameter settings for the algorithm, refer
to Appendix B.
Table 3.1 provides the 18 pan-cancer molecular signatures we identified from TCGA
Pan-Cancer data sets (for simplicity, the “pancan12” data sets). The name of each
attractor was determined by its similarities with known functional molecular feature
sets. If no similar gene set was found, the top feature was used to name the attractor. In
the table, we provided the top n features used to create the attractor features. Detailed
rankings of all 18 signatures are available under Synapse ID syn1714112, where all the
molecular features with a consensus MI greater than 0.5 are listed as members of the
signature [39].
We noted that related versions of the signatures, identified by attractors in this sec-
tion, have been previously identified in individual cancer types, often intermingled with
additional genes. However, our work identifies these signatures as pan-cancer biomolec-
ular events, sharply pointing to the underlying mechanism. Therefore the top molecular
features of the attractors can be appropriately used as biomarkers or for further under-
standing the underlying biology. For example, one of the attractors that we identified
(the “mitotic chromosomal instability” attractor, described below) has previously been
found in approximate forms among sets of genes described generally [40] as “prolifera-
tion” or “cell cycle related” markers, while the actual attractor points much more sharply
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to particular elements in the structure of the kinetochore-microtubule interface. In the
following sections, we will describe some of the signatures, their molecular/phenotypic
associations, and functional implications according to GSEA.
Table 3.1: Listing of the 18 attractor signatures
Name Top Members Comments
mRNA
LYM
SASH3, CD53, NCKAP1L, LCP2, IL10RA,




TPX2, KIF4A, KIFC1, NCAPG, BUB1,




COL3A1, COL5A2, COL1A2, THBS2,





CDH5, ROBO4, CXorf36, CD34, CLEC14A,
ARHGEF15, CD93, LDB2, ELTD1, MYCT1
Endothelial markers
“AHSA2”
AHSA2, LOC91316, PILRB, ZNF767, TTLL3,
CCNL2, PABPC1L, LENG8, CHKB CPT1B,
SEC31B
IFIT
IFIT3, MX1, OAS2, RSAD2, CMPK2, IFIT1,
IFI44L, IFI44, IFI6, OAS1
Interferon-induced
“WDR38”
WDR38, YSK4, ROPN1L, C1orf194, MORN5,
WDR16, RSPH4A, FAM183A, ZMYND10,
DNAI1
Genomically Co-localized mRNA
Continued on next page...
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SHARPIN, HSF1, TIGD5, GPR172A, ZC3H3,








mir-127, mir-134, mir-379, mir-409, mir-382,




“mir-509” mir-509, mir-514, mir-508
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be causal to the
expression of some of
the genes of the
LYM signature
Protein Activity
“c-Met” c-Met, Snail, PARP cleaved, Caspase-8 Related to apoptosis
“Akt” Akt, Tuberin, STAT5A
3.3 MES mRNA Signature
This signature is related to mesenchymal transition and invasiveness of cancer cells. The
signature contains numerous epithelial-mesenchymal transition (EMT) associated genes
[41]. It is also similar to numerous “stromal” or “mesenchymal” signatures. There is
evidence [42], however, that many genes of the signature are largely produced by trans-
differentiated cancer cells. We hypothesize that such cells, known to assume the duties
of cancer-associated fibroblasts in some tumors [5], may have become indistinguishable
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(even using laser capture microdissection) from stromal fibroblasts. The investigation of
the origin and functions of this signature will be further discussed in Chapter 4.
The MES signature was originally identified because of its association with tumor
stage [43]; specifically the signature appeareds only after a particular type-specific tumor
stage threshold has been reached.
The values of the MES signature are remarkably similar to the “stromal score” of the
ESTIMATE tumor purity computational tool (http://ibl.mdanderson.org/estimate)
measuring fibroblast infiltration [44]. As shown in Figure 3.1, the stromal scores and
the MES signature are positively correlated in 10 cancer types. Based on our previous
reasoning, however, we believe that this interpretation may not be fully accurate. It
will be important to find out to what extent some of the cells expressing part of these
mesenchymal markers may actually be transdifferentiated cancer cells, and whether the
estimated tumor purity may be affected by other types of normal cells instead of stromal
fibroblasts.
The co-regulated microRNAs most strongly associated with the MES signature across
cancer types are miR-199a, miR-199b, and miR-214. The DLK1 -DIO3 RNA cluster at-
tractor signature, described later, is also strongly associated with MES. Also, the protein
most strongly associated with the MES signature is Fibronectin.
3.4 Mitotic CIN mRNA Signature
This signature is related to mitotic chromosomal instability, characterized by overexpres-
sion of kinetochore-associated genes known [45] to induce CIN. Overexpression of several
of the genes of the signature, such as the top gene TPX2 and CENPA [46], has also been
previously found to be associated with CIN in research done independently. Included in
the mitotic CIN signature are key components of mitotic checkpoint signaling [47], such
as BUB1B, CDC20, and TTK (a.k.a. MSP1 ). Also among the genes in the signature
is MKI67 (a.k.a. Ki-67 ), which has been widely used as a proliferation rate marker in
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Figure 3.1: Scatter plots between ESTIMATE stromal scores and MES signature. Each plot
shows the relationship between MES signature and the stromal score in each cancer type. A
dot represents a sample. The MES signature expression level was calculated using the average
expression value of the 10 genes given in Table 3.1. Note that the MES signature does not exist
in LAML. Also there is no stromal scores provided for READ given its small sample size.
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cancer. Among transcription factors, we found MYBL2 (a.k.a. B-Myb) and FOXM1 to
be strongly associated with the signature. They are already known to be sequentially
recruited to promote late cell cycle gene expression [48] to prepare for mitosis. Many
among the genes of the attractor correspond to E2F pathway genes, which controll cell
division or proliferation. Among the E2F transcription factors, we found that E2F8 and
E2F7 are most strongly associated with the attractor.
A similar gene set comprising a “signature of chromosomal instability” [49] was pre-
viously derived from multiple cancer datasets purely by identifying the genes that are
most correlated with a measure of aneuploidy in tumor samples. This led to a 70-gene
signature referred to as “CIN70.” Indeend, 26 of these 70 genes appear as top 100 gene
members in the signature (P < 10−44 based on Fisher’s exact test. For top 100 gene
list, see Table C.1). However, several top genes of the signature, such as BUB1, KIF2C,
CENPA, CCNA2, and DLGAP5, are not present in the CIN70 list.
The signature is also similar to numerous known “proliferation” signatures found in
multiple cancer types [50, 26, 25, 51], but its sharp definition as an attractor signature
specifically points to the kinetochore-microtubule interface and associated kinesins. It
suggests a biological mechanism by which mitotic chromosomal instability in dividing
cancer cells gives rise to daughter cells with genomic modifications, some of which pass
the test of natural selection. Comparison with similar mitotic signatures in normal cells
may help pinpoint driver genes for malignant chromosomal instability, as will be further
discussed in Chapter 6.
Phenotypically, the signature is strongly associated with tumor grade as in many, if not
all, cancer types. Figure 3.2 shows associations between the values of the CIN signature
and the histological tumor grade in TCGA head and neck, kidney, and endometrial cancer
data sets. P value of the association between the CIN signature and the tumor grade is
1.96 × 10−5, 2.37 × 10−11, 2.11 × 10−26 (in each cancer type, respectively) according to
the Analysis of Variance (ANOVA) test. Consistently, a similar “gene expression grade
index” signature [52] was previously found differentially expressed between histologic
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Figure 3.2: Box plots connecting CIN signature with histological tumor grade. The box plots
show the quantiles (25% medium, 75%) of the CIN feature in each tumor grade in three cancer
types. The CIN feature is defined by the average of the top ranked genes as described in Table
3.1. P values were evaluated by the ANOVA test.
grade 3 and histologic grade 1 breast cancer samples, thus enabling the reclassification
of patients with histologic grade 2 tumors into two groups − high risk and low risk of
recurrence.
Two proteins strongly associated with the CIN signature are Cyclin B1 and CDK1.
Consistently, it is known that the cyclin B1-Cdk1 complex of cyclin-dependent kinase 1
is involved in the early events of mitosis, and that nuclear cyclin B1 protein may induce
chromosomal instability and enhance the aggressiveness of the carcinoma cells [53].
3.5 M+, M− Methylation and LYM mRNA
Signature
These three signatures are related to tumor infiltration by lymphocytes. We list them
together because they are strongly interrelated (Figure 3.3), even though each of the three
was independently derived using an unsupervised computational method. The presence
of LYM is accompanied by the presence of M+ and the absence of M- in all solid cancer
types, suggesting that the three signatures reflect the same biomolecular event, which
appears to be the infiltration of immune cells in tumor tissue. It is also worth noting that
the signatures do not correlate in LAML because the samples in that cancer type are
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Figure 3.3: Scatter plots connecting the LYM, M+ and M- signature in 12 cancer types.
Each dot represents a cancer sample. The horizontal and vertical axes measure the average
methylation values of the two methylation signatures, M- and M+, while the value of the
expression of the LYM feature is color-coded. In all three cases, the feature is defined by the
average of the top ranked genes as described in Table 3.1.
blood samples, thus making the concept of lymphocyte infiltration inapplicable. Indeed,
the LYM feature is positively correlated with the “leukocyte percentage,” as estimated by
pathologists under a microscope (Figure 3.4). There is also remarkable similarity (Figure
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Figure 3.4: Scatter plots demonstrating the pan-cancer correlation between the expression
value of the LYM feature with the leukocyte percentage estimation in TCGA slides data sets.
Each dot represents a cancer sample. The horizontal axis measures the expression value of the
LYM feature and the vertical axis measures percentage of leukocyte infiltration as estimated
under microscope.
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Figure 3.5: Scatter plots demonstrating the pan-cancer similarity of the LYM feature to the
ESTIMATE immune score measuring immune cell infiltration. Each dot represents a cancer
sample. The horizontal axis measures the expression value of the LYM feature and the vertical
axis is the ESTIMATE immune score. Note that the ESTIMATE did not provide scores for
READ, and the estimation of immune cell infiltration is not applicable in leukemia.
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Figure 3.6: Scatter plots demonstrating the pan-cancer association among LYM feature, M-
feature, and the miR-142 microRNA expression. Each dot represents a cancer sample. The
horizontal and vertical axes measure the average methylation values of the M- signatures and
the average expression values of the top genes of the LYM signature, while the value of the
expression of the miR-142 is color-coded.
3.5) between the LYM feature and the “immune score” of the ESTIMATE tumor purity
computational tool.
All three signatures have been previously found [54] to be associated with the expres-
sion of miR-142. The association with miR-142 is now confirmed in the pancan12 data
sets. We also found that miR-150 and miR-155 are strongly associated with the LYM
signature. Figure 3.6 shows the association among the M- signature, LYM signature,
and the miR-142 microRNA expression. Note that only 3 of the 12 cancer types contain
more than 50 samples that were profiled simultaneously by these three platforms. How-
ever, in all three cancer types, we clearly observed that LYM is positively correlated with
miR-142, while both are negatively correlated with M-.
The interrelationship of the LYM, M+, and M- signatures (as shown in Figure 3.3)
appears to be a consequence of the presence of different subclasses of cells (as opposed
to being a methylation switch inside the same cell), consistent with their assumed role
of measuring the extent of lymphocyte infiltration in the tumor. In other words, the
M+ methylation sites, normally unmethylated, are largely methylated in the infiltrating
leukocytes; and the M- methylation sites, normally methylated, are largely unmethylated
in the infiltrating leukocytes. Consistently, many of the genes methylated by the M-
signature are identical to those of LYM. Six of the 27 genes where the methylation sites
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of the M- signature locate (BIN2, TNFAIP8L2, ACAP1, NCKAP1L, FAM78A, PTPN7 )
are also among the 168 gene members in the LYM signature (P < 9.21× 10−7 based on
Fisher’s exact test. For genes and methylation site lists, see Table C.3 and C.4). The
significant overlap in the gene sets and the negative association between gene expression
in LYM and DNA methylation in M- are consistent with the notion that the absence of
DNA methylation is permissive for gene expression. This suggests that the expression
of the LYM signature in the infiltrating lymphocytes may be facilitated in part by the
hypomethylation of the M- signature.
The sharp definition of the LYM signature (being a pan-cancer attractor signature
pointing to a small number of genes at the core of coexpression) provides insights into the
precise nature of this leukocyte infiltration. Specifically, the top genes (SASH3, CD53,
NCKAP1L, LCP2, IL10RA, PTPRC, EVI2B, BIN2, WAS, HAVCR2, . . . ) point to a
specific type of lymphocytes [55]. Some of the top-ranked genes in the LYM signature,
including ADAP (a.k.a. FYB), are known to participate in a particular type of immune
response [56] in which the LFA-1 integrin mediates costimulation of T lymphocytes that
are regulated by the SLP-76–ADAP adaptor molecule. We have speculated [32] that these
infiltrating lymphocytes are T cells having undergone a particular type of co-stimulation,
which provided hypotheses for related adoptive transfer therapy.
Two proteins strongly associated with the LYM signature are two tyrosine kinases:
Lck (lymphocyte-specific protein tyrosine kinase) and Syk (spleen tyrosine kinase).
3.6 END mRNA Signature
Nearly all the top genes (Table 3.1) of this signature are endothelial markers. The top
gene, CDH5, codes for VE-cadherin, which is known to be involved in a pathway sup-
pressing angiogenic sprouting [57]. The second gene, ROBO4, is known to inhibit VEGF-
induced pathologic angiogenesis and endothelial hyperpermeability [58]. Consistently, the
END signature appears to be protective and antiangiogenic, stabilizing the vascular net-
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work. For example, 22 out of the 27 gene members of the END signature are among the
265 genes included in File S2 of a recent study [59] of renal cell carcinoma (P < 8.4×10−38
based on Fisher’s exact test) as being the most associated with patient survival. These
good-prognosis genes were intermixed in the same file with many poor-prognosis genes
of the CIN signature, suggesting that the CIN and END signatures are two of the most
prognostic features in renal cell carcinoma. Another recent study [60] also identified a
“common angiogenesis/endothelial cells metasignature” (Table 1 in the paper) which was
regulated in tumor angiogenesis. Among the top 20 genes of the signature, there are 18
genes also appear as the top 27 genes with consensus MI > 0.5 in the END signature
(Table C.5), the P value of such overlapping is 1.34× 10−53 based on Fisher’s exact test.
Interestingly, the MES and END attractors are positively associated with each other
(as shown in Figure 3.7) in the sense that overexpression of the END signature tends
to imply overexpression of the MES signature and vice-versa. This is consistent with
mutual exclusivity between angiogenesis and invasiveness and with related findings [61]
that VEGF inhibits tumor cell invasion and mesenchymal transition, while antiangiogenic
therapy is associated with increased invasiveness [62]. It may also help explain the para-
doxical, protective nature of signatures related to the MES signature in invasive breast
cancers [63].
3.7 Chr8q24.3 Amplicon mRNA Signature
This is the strongest pan-cancer amplicon signature. Figure 3.8 shows the genomic al-
terations in TCGA breast, ovarian, and liver cancer datasets as generated by OncoPrint
on the cBioPortal cancer genomic tool [64, 65]. The top genes in the chr8q24.3 amplicon
signature are consistently co-amplified together in multiple cancer types, which validates
that the coexpression patterns in mRNA were indeed caused by CNVs, while the other
identified genomically co-localized mRNA signatures may not have been.
Amplification in chr8q24 is often considered to be associated with cancer because of
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Figure 3.7: Scatter plots demonstrating the pan-cancer association between MES and END
feature. The horizontal and vertical axes measure the values of the MES feature and END
feature. The two signatures have positive correlation, although this association is not sufficiently
strong enough to merge the two attractors into one. This association suggests that the invasive
MES signature and the antiangiogenic END signature tend to be present simultaneously.
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Figure 3.8: Co-amplification of the chr8q24.3 amplicon signature in TCGA breast, ovarian,
and liver cancer data sets, output by OncoPrint. Each bar represents a sample in the data set. If
the bar is red, it means the gene to the left is amplified in that sample, while blue means the gene
is deleted. The figure only shows part of the samples which have copy number alterations. The
percentages to the left represent what proportion of the samples contain genomic alterations.
the presence of the MYC (a.k.a. c-Myc) oncogene at location 8q24.21. Indeed, MYC is
one of 157 genes in “amplicon 8q23-q24” thus was previously identified [66] in an extensive
study of the breast cancer “amplicome” derived from 191 samples.
We found, however, that the core of the amplified genes occured at location 8q24.3.
Core genes of the attractor were SHARPIN, HSF1, TIGD5, GPR172A (aka SLC52A2 ),
ZC3H3, EXOSC4, SCRIB, CYHR1, MAF1, and PUF60. HSF1 (heat shock transcription
factor 1) has been associated with cancer in various ways [67]. It was found [68] that HSF1
can induce genomic instability through direct interaction with CDC20, a gene member
of the mitotic CIN signature. Furthermore, HSF1 was required for the cell transforma-
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tion and tumorigenesis induced by the ERBB2 (a.k.a. HER2 ) oncogene responsible for
aggressive breast tumors [69]. The signature was also previously found to predict early
relapse in ER-positive breast cancers [70]. The other genes may also play important roles
in tumor progression. It is known that PUF60 can repress c-Myc via its far upstream
element (FUSE), although a particular isoform was found to have the opposite effect [71].
3.8 Other Pan-Cancer Signatures
Most of the pan-cancer signatures discussed in this section have not been fully investi-
gated, as either they have not been discovered until now, or there is very little published
research about them. However, because the pan-cancer coexpression patterns of these
signatures were significant in the permutation test, it is reasonable to hypothesize that
each of them represent an important biomolecular events in cancer.
“AHSA2” mRNA Signature
We observed that several noncoding RNAs (e.g. NCRNA00105 and NCRNA00201) are
in relatively high-ranked positions among their members. However, their functional roles
in cancer remain to be investigated.
IFIT (Interferon-Induced) mRNA Signature
The members of this signature are interferon-induced. For example, we observed large
enrichment of the genes of the signature among those upregulated by IFN-α in the side
population (SP) of ovarian cancer cells [72] from the list provided in Supplementary Table
S4 of that paper. Its authors concluded that tumors bearing large SP numbers could be
particularly sensitive to IFN-α treatment.
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Figure 3.9: The DLK1 -DIO3 cluster of ncRNAs. Shown is a screen capture from the UCSC
Genome Browser. The cluster of imprinted genes delineated by the DLK1 and DIO3 genes
(outside the shown region) is located on chromosome 14. We found that the corresponding
pan-cancer attractor signature does not contain any paternally inherited protein-coding genes.
It does contain the numerous ncRNA genes expressed from the maternally inherited homolog,
including the MEG3 long ncRNA gene.
“WDR38” mRNA Signature
While some characteristics of this signature are still unclear, we have found that one of
its key members, gene ZMYND10, is protective and associated with estrogen receptor
expression in breast cancer [73].
MHC Class II Genomically Co-localized mRNA Signature
This signature was found using the genomically co-localized version of the algorithm (see
Section 2.2). It is highly correlated with LYM.
GIMAP Genomically Co-localized mRNA Signature
Similar to the preceding signature, this genomically co-localized signature is also highly
correlated with LYM.
“RMND1” Methylation Signature
The functional role of the co-methylation of these sites whthin this signature is unclear.
50
DLK1 -DIO3 RNA Cluster Signature
This is the strongest pan-cancer multi-microRNA coexpression signature. It consists of
numerous noncoding RNAs (ncRNAs) within the DLK1 -DIO3 imprinted genomic region
of chr14q32. Figure 3.9 shows a screen capture of the genomic region from the UCSC
Genome Browser (http://genome.ucsc.edu/). We confirmed that the coexpression sig-
nature also includes the MEG3 long noncoding RNA, located at the upstream end of the
region. It may also include numerous small nuclear RNAs at the central region, but there
were no associated probe sets to confirm the coexpression. We found that this ncRNA
signature is associated with the MES signature. For example, the ranked list of mRNAs
most associated with the DLK1 -DIO3 ncRNA signature starts from POSTN, PCOLCE,
COL5A2, COL1A2, GLT8D2, COL5A1, SFRP2, and FAP.
Expression of the imprinted DLK1 -DIO3 ncRNA cluster is believed to be vital for the
development potential of embryonic stem cells [74], consistent with the hypothesis [75]
that mesenchymal transition in cancer reactivates embryonic developmental programs
and makes cancer cells invasive and stem-like. The DLK1 -DIO3 ncRNA signature was
also found to define a stem-like subtype of hepatocellular carcinoma associated with poor
survival [76]. The details of the regulation mechanism for this ncRNA cluster coexpression
in the DLK1 -DIO3 region are unclear.
“miR-509/miR-514/miR-508” microRNA Signature
These three microRNAs are co-localized at chrXq27.3. The biological meaning of this
signature remains to be clarified.
“miR-144/miR-451/miR-486” microRNA Signature
This is a three-microRNA signature related to erythropoiesis. The first two genes are
located in the bicistronic microRNA locus miR-144/451, highly expressed during ery-
throcyte development [77]. The mRNAs most associated to this microRNA signature are
hemoglobin-related: HBB, HBA1, HBA2, and ALAS2. The protein most associated with
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this signature is HER3. These three microRNAs were identified as promising biomarkers
for detection of esophageal cancer.
“c-Met” Protein Activity Signature
This protein coexpression signature contains c-Met, Snail, PARP cleaved, Caspase-8,
ERCC1, and Rbappears, combining the contribution of several pathways. Each of these
proteins [78, 79, 80, 81, 82, 83] has been related in various ways with resistance to
chemotherapy or apoptosis.
“Akt” Protein Activity Signature
The functional role of the coexpression of Akt, Tuberin, Stat5a proteins is unclear. We
do know that low levels of Stat5a protein in breast cancer are associated with tumor
progression and unfavorable clinical outcomes [84].
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Chapter 4
Further Investigation on the
Mesenchymal Transition Signature
The Mesenchymal Transition (MES) signature is one of the most prominent pan-cancer
signatures in all solid tumors. It contains mostly epithelial-mesenchymal transition
(EMT)-associated genes. However, the signature was also found in non-epithelial tumor
such as neuroblastoma and glioblastoma. It is a sufficient condition for tumor invasive-
ness to exceed a certain cancer-type-specific threshold, and the low expression of the
MES signature is also associated with prolonged time to recurrence in glioblastoma. In
a xenograft model, the signature was found to be only expressed by the human cancer
cells, not the mouse peritumoral cells, which is consistent with the hypothesis that the
MES signature is expressed by the cancer cell during transdifferentiation.
4.1 MES Signature and Tumor Invasiveness
The MES signature is associated with tumor stage, as it is significantly present only when
a particular level of invasive stage, specific to each cancer type, has been reached. This
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signature has been previously identified as representing a particular kind of mesenchymal
transition of cancer cells present in all types of solid cancers tested, leading to a pub-
lished list of top 64 genes [85]. This list was generated by a supervised algorithm, using
association with tumor stage. Indeed, 45 of these top 64 genes also appear in the top
100 gene members of the attractor signature (P < 4.87 × 10−94 based on Fisher’s exact
test. For gene list see Table C.2). Using the unsupervised attractor-finding algorithm,
or the supervised gene set identifying algorithm based on tumor stage, will both lead to
the same signature. This is yet another validation for the significant asspciation between
MES signature and tumor invasiveness.
Another way to investigate the associations between the signature and tumor stage
is to evaluate the enrichment of the top member genes of the signature in a list of the
most differentially expressed genes. Table C.6 demonstrates this phenomenon in three
data sets of different cancer types (breast, ovarian, and colon) that were annotated with
clinical staging information. The table provides a list of differentially expressed genes,
ranked by fold change (FC), when ductal carcinoma in situ (DCIS) progresses to invasive
ductal carcinoma, when ovarian cancer progresses to stage III, and when colon cancer
progresses to stage II. In all three cases, the attractor is highly enriched among the top
genes, with 46, 35, and 33 genes that appear as the top 100 genes of MES signature (as
marked by the “V” symbol), respectively. The corresponding P values, based on Fisher’s
exact test, are 9× 10−91, 1.21× 10−62, and 2.12× 10−67 in each cancer type [32].
4.2 MES Signature and Recurrence in Glioblastoma
We found that there is strong association of the signature with the phenotype “Days to
Tumor Recurrence” in TCGA glioblastoma multiforme (GBM) data set [86]. The days to
tumor recurrence pheotype is defined as the time period from initial treatment until the
date of diagnosis of the signs and symptoms of cancer following a period of remission.
Patients who did not experience improvement after therapy have a “null” entry in the
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Figure 4.1: Scatter plot showing the association between MES signature and time to tumor
recurrence. Each dot in the scatter plot represents one of the 99 patients for which the “Days to
Tumor Recurrence” phenotype has a non-null entry. The horizontal axis measures the average
of the top 10 genes’ expression levels of the MES signature shown in Table 3.1. The vertical
axis measures the days to tumor recurrence. The horizontal dotted line is drawn at the 3-year
cutoff point.
corresponding field.
In Figure 4.1, for each of the 99 samples where the “Days to Tumor Recurrence”
phenotype has a non-null entry, a dot is used to indicate the expression level of the
MES feature and the number of days to tumor recurrence. The figure reveals that,
55
Figure 4.2: Heat map of the top 10 genes of the MES signature in glioblastoma. The 99
samples are ranked in terms of the MES feature expression level, calculated as the average
values of the 10 genes shown in Table 3.1. The eight patients for which time to recurrence was
more than three years are highlighted in green at the 1st, 2nd, 3rd, 5th, 9th, 10th, 11th, and
15th positions, resulting in the rank sum of 56.
within the group of patients who experienced improvement after therapy, 8 patients
whose tumors recurred more than three years following therapy have very low values of
the MES feature. Figure 4.2 shows a heat map of the top 10 genes, where the samples
are ranked in terms of the expression of the MES feature. The eight patients for which
time to recurrence was more than three years are highlighted in green. The rank sum
for these eight patients is 1+2+3+5+9+10+11+15 = 56. The rank sum is a suitable
measure of this particular observed aspect (i.e. the association of the proloned “Days to
Tumor Recurrence” phenotype with the expression of a gene), in which absence of gene
expression is required for exceptionally long time to recurrence. The probability of the
rank sum being less than 56 due to pure chance is estimated, as the relative frequency
of such occurrences after randomly permuting the phenotypes ten million times and
recalculating the rank sum, concluding that P < 2× 10−7.
We then used the rank sum metric to identify which, among individual genes of the
MES signature that define the metagene, have the best score. Expecting that some of
them would have a rank sum lower than 56, we were surprised to find that the best
scoring gene was COL5A1, with rank a sum equal to 78, followed by COL1A2, with rank
sum equal to 88. In other words, the score of the MES feature is significantly better than
that of any of its individual component genes. Even more striking is the fact that after
doing an exhaustive search among all 12,042 genes in the data set, the top ranked gene
(EFEMP2 ) had a rank sum equal to 75, worse than that of the MES feature, which is 56.
These results suggest that the signature identified comprises a synergistic collection of
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Table 4.1: Top genes in terms of the rank sum for the prolonged time to recurrence.
genes corresponding to a biological mechanism of mesenchymal transition, which, when
absent, is associated with increased time period to tumor recurrence in GBM.
Table 4.1 shows a listing of the top 30 individual genes in terms of their rank sum for
the “Days to Tumor Recurrence” phenotype. There are 8 genes which also appear as the
top 50 genes of MES signature. These are marked by the “V” symbol, demonstrating the
strong enrichment (P = 3 × 1013) of MES signature in this unbiased collection of genes
associated with the phenotype.
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Figure 4.3: Kaplan-Meier curves comparing samples with high vs. low levels of the MES
signature. The 545 tumor samples were partitioned into two groups of equal size depending
on their levels of the MES feature. Shown are the Kaplan-Meier curves for the corresponding
samples with entries in the “Days to Tumor Recurrence” field.
To evaluate the association in more general terms, we separated the entire set of
545 tumor samples into two groups of equal size, containing high vs. low levels of the
mesenchymal transition metagene. Within the 99 samples containing a “Days to Tumor
Recurrence” field, there were 44 “low level” and 55 “high level” samples. We performed
Cox regression between days to tumor recurrence and the expression level of the signa-
ture. Figure 4.3 shows the corresponding Kaplan-Meier cumulative survival curves [87],
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Figure 4.4: Scatter plot showing association between CD44 and MES signature. Each dot in
the scatter plot represents a glioma sample from the NCI Rembrandt dataset. Dots are color
coded red for glioblastomas and blue for lower grade gliomas. Expression of the MES signature
is represented by the MES feature.
resulting in a clearly seen association with statistical significance of P = 0.0065, using a
logrank test.
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4.3 Association Between MES Signature and CD44
While all cases in the TCGA GBM data set have been diagnosed as glioblastoma, the de-
layed recurrence in these 8 cases mentioned in the previous section is also a characteristic
of lower-grade gliomas. We investigated whether lower-grade gliomas are also charac-
terized by lower levels of the signature by analyzing the NCI Repository for Molecular
Brain Neoplasia Data (Rembrandt) data set (National Cancer Institute. 2005. REM-
BRANDT home page: http://rembrandt.nci.nih.gov. Accessed November 2011),
which included gene expression from both glioblastoma as well as various types of lower-
grade gliomas. Table 4.2 demonstrates that 6 of the 30 most differentially expressed genes
between GBM and lower-grade glioma are among the top 50 genes of the MES signature,
as marked by the symbol “V” (P = 1.36× 10−10 based on Fisher’s exact test). Further-
more, we found strong correlation (r = 0.66) between the expression levels of the MES
feature and the cancer stem cell marker CD44 (P < 2 × 10−16 based on fitting Pearson
correlation coefficient to t-distribution). Figure 4.4 shows the corresponding scatter plot.
Recent studies have shown that high levels of CD44 are expressed in cancer stem
cells isolated from several different types of tumors [88] − a concept that is still evolving
− with CD44 being expressed in a variety of other cell types. CD44 has been found
in a cell population enriched for glioma stem cells [89]. It is also widely expressed in
glioblastoma, and increased levels are associated with glioma progression and resistance to
therapy [90]. Related versions of the same signature were previously found to be associated
with resistance to neoadjuvant therapy in breast cancer [91]. These results are consistent
with the finding that EMT induces cancer cells to acquire stem cell properties [75].
It has been hypothesized that EMT is a key mechanism for cancer cell invasiveness
and motility [92, 93, 94]. The attractor signature, however, appears to represent a more
general phenomenon of transdifferentiation present even in nonepithelial cancers such as
glioblastoma, Ewing’s sarcoma, and neuroblastoma, as will be discussed in the following
section.
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Table 4.2: Top differentially expressed genes in GBM versus lower grade glioma.
Analysis of gene expression data enabled the classification of glioblastomas into various
subtypes [26, 18]. These subtypes also present in lower grade gliomas [95] with distinct
features, each of which is characterized by the presence of particular genes. Interestingly,
CD44 was found to be overexpressed in the mesenchymal subtypes in all these cases.
A feature of our current results, however, is that the MES signature presented in this
thesis reflects a biological process applicable to multiple cancer types, as it was derived
by analyzing data sets from many different cancers, as opposed to using classification
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methods on glioma samples alone to identify subtypes. Furthermore, the association
with the phenotype is found in the absence (low expression), rather than the presence,
of the signature.
4.4 Comparing the MES Signature with Other
Mesenchymal Subtypes in Glioma
To confirm that the observed association with the time to recurrence is more related to the
presence of the mesenchymal transition signature (rather than to the classification into a
mesenchymal subtype in [26]), we performed multivariate Cox regression on days to tumor
recurrence, using both the MES feature and the four subtypes in [26] as covariates. The
subtype variable is a categorical variable with four types (Mesenchymal, Classical, Neural,
and Proneural). To infer the samples whose subtypes were not given in the original paper,
we performed a ten-nearest neighbor imputation based on the signature genes of the four
subtypes as given in [26]. The result shows that the categorical variables did not pass a
significance level of 0.05, where the most significant subtype is the mesenchymal subtype
with P = 0.0654. The significance level of the association between MES feature and
survival is P = 0.0012, demonstrating that the time to recurrence is most significantly
associated with the MES signature derived by the iterative algorithm. The results of Cox
regression are shown in Table 4.3.
To further compare the mesenchymal transition signature with that of the “Mesenchy-
mal” subtype of [26], we created a metagene for the latter so that we could evaluate its
association with the “Days to Tumor Recurrence” phenotype as measured by the rank
sum. This was created using the gene list as described in the supplementary information
of the paper (available at http://tcga-data.nci.nih.gov/docs/publications/gbm_
exp). Specifically, in the associated data file containing the expression values and sub-
type calls for the Core TCGA samples using the unified scaled data, there were 216 genes
labeled as mesenchymal. These genes were ranked in terms of their power to represent
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Cox Regression on MES Feature
Hazards Ratio (95% CI) P value
MES 1.329 (1.119−1.578) 0.0012
Cox Regression on Categorical Subtypes
Hazards Ratio (95% CI) P value
Overall 1.000
Classical 0.939 (0.666−1.326) 0.7218
Mesenchymal 1.391 (0.979−1.974) 0.0654
Neural 0.973 (0.605−1.565) 0.9109
Proneural 0.787 (0.544−1.138) 0.2028
Table 4.3: Cox regression using MES feature or subtypes in GBM as covariates.
the mesenchymal phenotype, as determined by the differences between each gene’s mes-
enchymal centroid component and the centroid component of the remaining subtypes.
This can also be regarded as the log-fold change between the gene’s mean value in the
mesenchymal subtype and the gene’s overall mean [96] (as quoted in the data file con-
taining the ClaNC840 gene list and centroids). Based on that ranking, we selected the
top 10 genes in the list, so that the sizes of the two features to be compared are identical.
The value of the rank sum was 120 (it would have been a rank sum of 151, if using all 216
genes). This should be compared with the corresponding value of 56 for the MES feature
and with the other entries of individual genes in Table 4.1. These results further confirm
that the observed association with days to tumor recurrence is due to the multi-cancer
MES signature, whose corresponding feature, remarkably, has lower rank sum than any
individual gene.
4.5 Source of MES Signature
This signature is related to mesenchymal transition and invasiveness of cancer cells. It
is similar to numerous “stromal” or “mesenchymal” signatures. Given the heterogene-
ity of cells in tumors, the MES signature suggests an underlying biological mechanism
associated with cancer invasion. It could also reflect the superposition of several mecha-
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nisms. Among other possibilities, the fibroblast-like cells producing the signature could
be derived from multiple sources, such as bone marrow, local stroma, or cancer cells after
undergoing a mesenchymal transition. A fundamental question, therefore, is which genes
among the signature genes are expressed by the cancer cells and which are expressed by
the adjacent microenvironment?
We also observed that there is a striking similarity between the set of genes in the
signature and a subset of the genes that are known to be expressed at a lower level
when mouse embryonic fibroblasts are reprogrammed into induced pluripotent stem cells
[97] (results available in a pre-print format on nature precedings: http://hdl.handle.
net/10101/npre.2011.5924.1). Because it is known [98] that a mesenchymal-epithelial
transition (MET) is part of the reprogramming of mouse fibroblasts into stem cells, we
reasoned that, conversely, the signature may correspond to some kind of EMT-related
transition from a stem-like state to a fibroblast-like state used in early embryogenesis.
Therefore, we hypothesized that many genes in the signature may be expressed by can-
cer stem cells (CSCs) passing through some type of EMT. Furthermore, because of the
prominent presence of inhibin-A (INHBA) in the signature, we hypothesized that activin
A (INHBA dimer) signaling may be responsible for the signature.
To test these two hypotheses and to identify which among the genes of the signature, if
any, are expressed by the cancer cells, we used xenograft models implanting human cancer
cell lines into NCr nude mice. Some of the implanted cells had previously been stably co-
transfected with either follistatin (FST )-pReceiver-Lv105 or INHBA pReceiver-Lv105
(GeneCopoeia; Rockville, MD). Seven mice were implanted with INHBA-transfected
NGP cells, six with FST and five with control NGP cells. All mouse experiments and
breeding were conducted according to protocols approved by the Columbia University
IACUC. Mice were euthanized when estimated tumor weight reached 1.5 g, followed by
collection of contralateral kidney and tumor. Tumor tissues were snap frozen for RNA
isolation.
Each of the resulting tumors was harvested and profiled for gene expression using
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Figure 4.5: Scatter plots showing the association among MES signature, COL11A1, and
SNAI2. Each dot represents a sample. The x axis measures the expression value of MES
feature. The y axis measures the expression value of COL11A1 gene. The expression value of
SNAI2 is color-coded.
human (Affymetrix HG-U133A 2.0) and mouse microarrays (Affymetrix 430 A2.0). The
data set, corresponding to 18 tumors profiled separately with human and mouse microar-
rays, has been deposited into NCBI’s Gene Expression Omnibus (GEO) and is available
through accession number GSE34481 [42].
Based on the genes which are consistently associated with the signature, we found that
Slug (SNAI2 ) is one of the most prominent EMT-inducing transcription factors that is
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Figure 4.6: Scatter plots showing the association among MES signature, COL11A1, and
SNAI2 in human and mouse cells. Each dot represents one of the 18 samples. The x axis
measures the expression value of MES feature. The y axis measures the expression value of
COL11A1 gene. The expression value of SNAI2 is color-coded.
highly coexpressed, if not a member of, the MES signature across various cancer types.
Another gene that is of particular interest to us is COL11A1. As shown in Section 4.1,
COL11A1 is consistently the top gene with the highest association with tumor stage, thus
making it a perfect “proxy” gene for tumor invasiveness. Therefore, although COL11A1
does not appear to be the top 10 genes of the MES signature, it may represent a second
stage of the mesenchymal transition where tumors have already obtained mobility and
start invasion. The MES signature, on the other hand, represents an earlier biological
event in which a tumor initiates transdifferentiation in order to gain mobility and invade
the surrounding environment. Figure 4.5 shows that Slug is indeed coexpressed with MES
signature and COL11A1 in various cancer types, but not leukemia. The remarkable
continuity of the dots shown in the scatter plots suggest a dynamic and potentially
reversible process as the human cancer cells pass through mesenchymal transition.
We found very different expression levels (Figure 4.6) for most genes in humans and
mice, suggesting that interspecies hybridization is minimal, as previously reported [99].
Using COL11A1 as a proxy, we ranked the 18 samples accordingly and investigated if
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most of the top genes in MES signature were co-expressed with COL11A1. We found this
to be the case in human cells only. For example, Figure 4.6 shows color-coded scatter plots
of the 18 samples for the expression of SNAI2 in terms of the expression of the main genes
of the signature, COL11A1, and the MES feature (similar to the scatter plots of Figure
4.5, suggesting an identical biological process). This demonstrates that this coexpression
is clearly present in the human cells, but absent in the mouse cells. Specifically, seven
samples had high or intermediate levels of coexpressed genes in the human cells, while
the remaining 11 had relatively lower levels. Therefore, we regrouped the 18 samples,
according to the expression level of human COL11A1 and MES signature, into seven
samples with high or intermediate MES expression, and eleven with low MES expression.
Based on this partition, we performed differential expression analysis using significance
analysis of microarrays (SAM) [100], implemented in the Bioconductor package samr.
We define a differentially expressed gene to be significant if it has both a Q value (false
discovery rate, or FDR) [101] less than 0.05 and a fold change (FC) greater than 2.
Based on this partition, we identified 299 unique, significantly (both Q < 0.05 and FC
> 2) upregulated genes, 31 of which (COL11A1, COL3A1, COL5A2, THBS2 , COL5A1,
VCAN, COL6A3, SPARC, FBN1, COL1A1, PDGFRB, EMILIN1, CDH11, GLT8D2,
CTSK, PRRX1, BGN, ISLR, ASPN, NID2, FN1, SULF1, GPR124, OLFML1, ACTA2,
DCN, CALD1, ECM2, FSTL1, MRC2, and LOXL2 ) belong to the top 100 genes in
MES signature (P = 2.8 × 10−27), as well as SNAI2 (Slug) and VIM (Vimentin). The
presence in this list of ACTA2 (α-SMA), FN1 (Fibronectin), SNAI2, and VIM, together
with many of the other EMT markers mentioned above, indicates that some human
cancer cells underwent EMT. Other EMT-inducing transcription factors (SNAI1 [Snail],
TWIST1 [Twist], ZEB1, ZEB2, SIP1, and FOXC2 ) were not upregulated, while the
upregulation of SNAI2 was very significant (Q < 3× 10−4 and FC = 5.22).
The heat map in Figure 4.7 shows the co-expression of the above 31 significantly
upregulated genes. INHBA is not included in the list because its expression was ma-
nipulated by the transfections with consistent results. Furthermore, the transfections of
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Figure 4.7: Heat map showing differentially expressed human and mouse genes. The expres-
sion levels are color-coded, with the lowest value being blue and the highest value being red for
each gene.
cancer cells with either INHBA (labeled “I”) or FST (labeled “F”) did not have any effect
on the presence of the signature (the corresponding expression levels were consistent with
the transfections and did not affect the expression of the other genes in the signature).
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Next, we analyzed the mouse microarray data to identify genes correlated with the
presence of the cancer MES signature in the human cells. We found 32 significantly (both
Q < 0.05 and FC > 2) downregulated mouse genes in the presence of the human cancer
EMT signature. Among them, the top two genes with the highest fold change (12.3
and 11.8 respectively) were the adipocyte markers ADIPOQ (adiponectin) and CFD
(adipsin). We observed that these genes were strongly coregulated with many other
adipocyte markers, including FABP4 (fatty acid binding protein 4, a.k.a. aP2). This
cluster of adipocyte markers, whose downregulation in the mouse cells is strongly associ-
ated with the upregulation of the EMT signature genes in human cells, is also shown in
the heat map of Figure 4.7. Many of these genes are known as adipocyte differentiation
markers, and their downregulation is consistent with the finding that adipocytes are de-
differentiated as they encounter adjacent invading cancer cells in a “vicious cycle” [102]
of a complex interaction which facilitates cancer cell invasiveness. The observed down-
regulation of adipocyte markers in the adjacent mouse tissue, associated with the MES
gene expression of the human cells, provides a potential molecular control mechanism
of microenvironmental contextual interactions in accordance with previously published
results.
In summary, we have shown that MES signature present in multiple cancer types was
found in our xenograft experiments not to be expressed by the stromal cells, but instead
by the human cancer cells themselves in vivo. Prior to our experiments, this was an open
question, because the signature contains genes, such as α-SMA, that are typically found in
stromal cells such as fibroblasts. Therefore, our results are consistent with the hypothesis
that mesenchymal transition can convert cancer cells into mesenchymal, fibroblast-like
cells that may well assume the duties of cancer-associated fibroblasts in some tumors [5].
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Chapter 5
Predicting Breast Cancer Prognosis
Using Attractor Signatures
The pan-cancer attractor signatures identified by the iterative approach were hypoth-
esized to correspond to molecular events that are prognostic in multiple cancer types,
including breast cancer. This hypothesis was tested when we participated in the Sage
Bionetworks-DREAM Breast Cancer Prognosis Challenge (BCC). In order to utilize the
power of the signatures in breast cancer, we identified the specific conditions where the
prognostic value of each signature was maximized, including several prognostic breast
cancer-specific attractor signatures and metagenes. The identified features were used to
build an ensemble model consisting of submodels, such as Cox proportional hazards ra-
tio models, gradient boosted models (GBM), and customized K-nearest neighbor (KNN)
models to predict survival. This ensemble model won “Best Performer” of the challenge
after being validated in a newly generated patient data set. It also significantly out-
performed the models built only on clinical covariates, which indicates the significant
additional prognostic values added by the attractor molecular features.
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5.1 The Sage Bionetworks-DREAM BCC
Medical tests that incorporate molecular profiling of tumors for clinical decision-making
(predictive tests) or prognosis (prognostic tests) are typically based on models that com-
bine values associated with particular molecular features, such as the expression levels
of specific genes. These genes are selected after analyzing rich gene expression data
sets (acquired from testing patient tumors) annotated with clinical phenotypes such as
drug responses or survival times. A computational technique is typically used to identify
a number of genes that, when properly combined, are associated with a phenotype of
interest in a statistically significant manner.
There are, however, vast numbers − tens or hundreds of thousands − of potentially
relevant molecular features to choose from when developing a model, making it difficult
to precisely identify those at the core of the biological mechanisms responsible for the
phenotype of interest. Spurious or suboptimal predictions may occur, and the end result
may be a model that only partly reflects physiological reality. Such a model may still be
clinically useful, but there is room for improvement.
The Sage Bionetworks-DREAM Breast Cancer Prognosis Challenge was an open chal-
lenge to build computational models that will accurately predict breast cancer survival
(hereinafter referred to as the Challenge) [103]. It provided the Challenge participants
with a common platform for data access − the Sage Synapse platform − and blinded
evaluation of model accuracy in predicting breast cancer survival on the basis of molecu-
lar and clinical features. The Challenge also represented a crowdsourced research study
which offered the opportunity to assess whether a community challenge would generate
models of breast cancer prognosis commensurate with (or exceeding) current best-in-class
approaches.
The initial phases of the Challenge were based on the partitioning of the rich METABRIC
breast cancer data set [104] (which includes molecular − gene expression and copy num-
ber − clinical, and survival information from 1981 patients) into two subsets: a training
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set and a validation set. Participants’ computational models were developed on the train-
ing set and evaluated on the validation set, using a real-time leaderboard to record the
performance (as determined with concordance index (CI) values, defined below) of all
submitted models. During the final phase of the Challenge, participants were given ac-
cess to the full set of the METABRIC data, which had been renormalized for uniformity
by Sage Bionetworks using eigen probe set analysis [105]. At that time, the computational
models could be trained on the full set and submitted for evaluation against a newly gen-
erated validation data set of patients, referred to as the Oslo Validation (OsloVal) data
set [103]. Therefore, the numerical values for the results that we present here use the
full METABRIC data set to maximize accuracy, whereas our computational models were
developed using the originally available training data sets.
A CI [106] was the numerical measure used to score all Challenge submissions on
the leaderboard. In this context, the CI is a score that applies to a cohort of patients
(rather than an individual patient), evaluating the similarity between the actual ranking
of patients in terms of their survival and the ranking predicted by the computational
model. CI measures the relative frequency of accurate pairwise predictions of survival
over all pairs of patients for which such a meaningful determination can be achieved and,
therefore, is a number between 0 and 1. The average CI for random predictions is 0.5. If
a model achieves a CI of 0.75, the model will correctly order the survival of two randomly
chosen patients three out of four times.
The METABRIC data set included both disease-specific (DS) survival data, in which
all reported deaths were determined to be due to breast cancer (otherwise, a patient was
considered equivalent to a hypothetical, still-living patient with reported survival equal
to the time to actual death from other causes), and overall survival (OS) data, in which
all deaths are reported even though they could potentially be due to other causes. Our
research, performed in the context of the Challenge, used mainly DS survival–based data
(unless otherwise noted). The CI scores referring to the METABRIC data set presented
in this paper were also evaluated using DS survival data. We did this is because we found
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that the CIs for models developed using DS survival-based data from the METABRIC
data set were significantly higher than those obtained when the OS survival-based data
were used. Furthermore, we found that DS survival-based modeling did not need to
include age as a prognostic feature as much as OS survival–based modeling did, which
suggests that OS survival-based modeling cannot predict survival using molecular features
as accurately as DS survival-based modeling, and instead needed to make use of age, which
is an obvious feature for predicting survival even in healthy people.
The initial phases of the Challenge consisted of participants training their prognostic
computational models using a subset of samples from the full METABRIC data set as a
training set, whereas the remaining subset was used to test models by evaluating the CI
scores in a real-time leaderboard. The survival data and the corresponding scoring of the
OsloVal data set were OS survival–based. Accordingly, the Kaplan-Meier survival curves
presented in this chapter involving OsloVal are OS survival-based [73].
5.2 Identifying Prognostic Features
As a first task, we quantified the prognostic ability of the expression level of each indi-
vidual gene by computing the CI between the expression levels of the gene in all patients
and the survival of those patients (Table 5.1). Specifically, the CIs reported in Table 5.1
are the CIs that we would calculate if the prognostic model consisted exclusively of the
expression level of only one specific gene. For example, consider the CDCA5 gene (listed
at the top of the left-hand column of Table 5.1). If we ranked all patients in terms of their
CDCA5 expression levels, from highest to lowest, and then ranked all patients in terms
of their survival times, from shortest to longest, these two rankings would yield a CI of
0.651. This means that, if we were to randomly select two patients from the METABRIC
data set, the one who has higher expression of CDCA5 will have the shorter survival
time 65.1% of the time. Because CDCA5 expression is associated with poor prognosis
(that is, the higher the expression, the shorter the survival), we refer to CDCA5 as a poor
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Inducing Genes Protective Genes
Gene Symbol CI CIN Gene Symbol CI
CDCA5* 0.651 V FGD3 0.352
UBE2C 0.644 V SUSD3 0.358
CCNB2 0.643 V MAPT 0.372
TROAP 0.643 V LRRC48 0.374
AURKA 0.642 V PARP3 0.374
FAM83D 0.64 CIRBP 0.375
MELK 0.64 V BCL2 0.376
KIF20A 0.639 V CASC1 0.377
EXO1 0.639 V CCDC170 0.377
CCNA2 0.638 V HS.570988 0.378
CENPA* 0.638 V TMEM26 0.378
CENPE 0.637 C14orf45 0.38
TPX2* 0.637 V CBX7 0.38
GTSE1 0.637 V GSTM2 0.38
HJURP 0.636 V C7orf63 0.381
KIF14 0.636 V TMEM101 0.382
CDC20 0.636 V HS.144312 0.382
RACGAP1 0.636 V PGR 0.382
PLK1* 0.636 V NICN1 0.382
CKAP2L 0.635 V ABAT 0.382
NCAPG* 0.635 V WDR19 0.383
FOXM1 0.635 V CYB5D2 0.383
PTTG1 0.634 PREX1 0.383
CEP55 0.634 HS.532698 0.384
BUB1* 0.633 V LRIG1 0.384
KIF2C* 0.633 V PHYHD1 0.384
POLQ 0.633 NME5 0.384
AURKB 0.632 V LZTFL1 0.384
MCM10 0.632 V CYB5D1 0.385
C1orf106 0.632 STAT5B 0.386
Table 5.1: Individual gene expression and survival.
survival-inducing gene (or simply, an “inducing gene,” displaying a CI that is significantly
greater than 0.5).
At the opposite end of the spectrum was the FGD3 gene, which had a CI of 0.352 (See
Table 5.1, right-hand column). This CI indicates that if we were to randomly choose two
patients from the METABRIC data set, then the one with lower FGD3 expression levels
will have the shorter survival time 64.8% (100% minus 35.2%) of the time. Because high
levels of FGD3 expression were associated with a good prognosis (that is, the higher the
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expression, the longer the survival), we refer to FGD3 as a survival-protective gene (or a
“protective” gene, which is one that displays a CI significantly less than 0.5). Table 5.1
shows two expanded lists of ranked genes: one with the 30 most inducing genes (those
with the highest CIs) and one with the 30 most protective genes (those with the lowest
CIs). If a gene was profiled by multiple probes, we chose the probe with the highest
difference from the average CI for random predictions, 0.5.
5.2.1 Mitotic CIN Signature
We represented the mitotic CIN attractor metagene with the CIN feature − the average
of the expression levels of the 10 top-ranked genes from the CIN signature. By ranking
individual genes in terms of their, we essentially rediscovered the mitotic CIN attractor
metagene by identifying the genes for which expression was most associated with poor
prognosis in the METABRIC data set. Indeed, 7 out of the 10 genes of the CIN feature
that we used in the Challenge were among the 30 genes listed in the left column of
Table 5.1; Genes identified by asterisks were among the 10 top-ranked genes of the CIN
attractor metagene and were used in the model along with KIF4A, KIFC1, and NCAPH.
Furthermore, 24 of the 30 genes listed in the left column of Table 5.1 were among the
top 50 genes of the CIN signature (the P value for such overlap is less than 4.28× 10−67,
based on Fisher’s exact test).
Our results regarding this, and other attractor signatures, were validated in a statis-
tically significant manner in the OsloVal data set despite its relatively small size (184
samples). For example, Figure 5.1 shows the Kaplan-Meier cumulative survival curves
of the CIN feature for the METABRIC (P < 2× 10−16 using log-rank test) and OsloVal
(P = 0.0028 using log-rank test) data sets, comparing tumors with high and low values of
the CIN feature. This data confirmed that poor prognosis was associated with expression
of the mitotic CIN signature.
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Figure 5.1: Kaplan-Meier cumulative survival curves of breast cancer patients (over a 15-year
period) on the basis of the mitotic CIN signature expression − represented by the CIN feature
− in the METABRIC and OsloVal data sets. Patients were divided into equal-sized “high” and
“low” CIN-expressing subgroups according to their ranking with respect to expression values of
the CIN feature. High expression of the mitotic CIN attractor metagene was associated with
poor survival in both data sets. P values derived using the log-rank test in the two data sets
were less than 2× 10−16 and 0.0028, respectively.
5.2.2 MES Signature
We represent the MES signature with the MES feature, as defined by the average ex-
pression of the top 10 genes. As mentioned in Chapter 4, the signature is expressed in
high amounts only in tumor samples from patients whose cancer has exceeded a defined
stage threshold, which is type–specific. For example, in breast cancer, the MES signature
appears early, when in situ carcinoma becomes invasive (stage I); in colon cancer, it is
expressed when stage II is reached; and in ovarian cancer, it is expressed when stage III
is reached (see Chapter 4). Identification of stage-specific differentially expressed genes
in these three cancers reveal strong enrichment of the signature. We found that this
differential expression results from the fact that the signature is present in some (but
not all) samples in which the stage threshold is exceeded, but never in samples in which
the stage threshold has not been reached. That is, the presence of the signature implies
tumor invasiveness, but its absence is uninformative.
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In breast cancer, we found the prognostic ability of the MES feature was not significant
individually. We reasoned that this lack of prognostic power is explained by the fact that
the presence of the MES signature in breast cancer implies that the tumor is invasive, but
this was the case anyway for nearly all patients in the METABRIC data set. Therefore, we
hypothesized that the MES signature would be prognostic only for very early stage breast
cancer patients, which we defined by the absence of positive lymph nodes combined with
a tumor size less than 30 mm. This restriction improved prognostic ability, but it still
did not reach a level of statistical significance. However, we found that, in combination
with the other features that we used, this restricted version of the MES signature was
helpful for the performance of our final model. This was confirmed, as we describe below,
by the fact that the prognostic power of our final model was reduced when eliminating
the MES feature.
5.2.3 LYM Signature
We represent the LYM signature by the LYM feature. By itself, the LYM feature was
slightly protective (CI < 0.5) in the METABRIC data set but was not significantly
associated with prognosis. Therefore, we used a “trial and error” approach by testing
the prognostic power of the feature on various subsets of patients grouped on the basis of
histology, estrogen receptor (ER) status, etc. The LYM feature was strongly protective in
ER-negative breast cancer in the METABRIC data set. This observation was validated
in the OsloVal data set; Figure 5.2 shows Kaplan-Meier survival curves for ER-negative
patients from the METABRIC data set (P = 0.0034 using log-rank test) and OsloVal
data set (P = 0.0049 using log-rank test). In both cases, the curves compare tumors with
high and low values of the LYM feature.
By contrast, the effect on prognosis was reversed for patients who had ER-positive
cancers and multiple cancer cell–positive lymph nodes; Figure 5.2 shows the Kaplan-
Meier survival curves for METABRIC patients with ER-positive status and more than
four positive lymph nodes, comparing tumors with high and low values of the LYM
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Figure 5.2: Kaplan-Meier cumulative survival curves of breast cancer patients (over a 15-year
period) on the basis of the LYM signature expression − represented by the LYM feature − in
METABRIC and OsloVal data sets. The ER-negative breast cancer patients were divided into
equal-sized high and low LYM-expressing subgroups according to their ranking with respect
to expression values of the LYM feature. High expression of the LYM attractor metagene was
associated with improved survival in both data sets. P values derived using the log-rank test
in the two data sets were 0.0032 and 0.0049, respectively. ER-positive breast cancer patients
with more than four positive lymph nodes were also divided into equal-sized high and low
LYM-expressing subgroups according to their ranking with respect to expression values of the
LYM feature. In contrast to ER-negative, high expression of the LYM attractor metagene was
associated with poor survival in this patient subset. The P value derived using the log-rank
test was 0.0486.
feature (P = 0.0486 using log-rank test). There were only 19 corresponding samples in
the OsloVal data set, insufficient for validation of this reversal.
The composition of this gene signature indicates that a signaling pathway that includes
the protein tyrosine phosphatase receptor type C (also called CD45, encoded by PTPRC )
and leukocyte surface antigen CD53 has a role in patient survival.
5.2.4 FGD3 -SUSD3 Metagene
As shown in Table 5.1, the FGD3 and SUSD3 genes were found to be the most protec-
tive ones in the METABRIC data set, with CIs equal to 0.352 and 0.358, respectively.
Therefore, we considered them promising candidates to be included as features in our
prognostic model. The two genes are genomically adjacent to each other at chromosome
9q22.31. In our final prognostic model, we used the FGD3 -SUSD3 metagene, which was
defined by the average of the two expression values.
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Figure 5.3: FGD3 -SUSD3 metagene. (A) A scatter plot of the expression of SUSD3 versus
FGD3 in the METABRIC data set shows a high variance in the expression of both genes at high
expression levels. On the other hand, low expression of one strongly suggests low expression of
the other in breast tumors. (B) ER-negative breast tumors tended not to express the FGD3 -
SUSD3 metagene, whereas ER-positive breast tumors may or may not have expressed the
FGD3-SUSD3 metagene, as shown by the scatter plot between the metagene and ESR1 gene.
(C) Kaplan-Meier cumulative survival curves of breast cancer patients over a 15-year period
on the basis of FGD3 -SUSD3 metagene expression in the METABRIC and OsloVal data sets.
Patients were divided into equal-sized high and low subgroups according to their ranking with
respect to FGD3 -SUSD3 metagene expression values. Low levels of FGD3 -SUSD3 metagene
expression were associated with poor survival in both data sets. P values derived using the
log-rank test in the two data sets were less than 2× 10−16 and 0.0028, respectively.
Scatter plots in Figure 5.3A of the METABRIC expression levels of FGD3 versus
SUSD3 showed that the two genes did not appear to be co-regulated when one or the other
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gene was highly expressed, but the genes did appear to be simultaneously silent (that is,
low expression of one gene implies low expression of the other). The CIs for the FGD3 -
SUSD3 metagene and the estrogen receptor 1 (ESR1 ) gene in the METABRIC data set
were 0.346 and 0.403, respectively, indicating that the lack of FGD3 -SUSD3 expression
was more strongly associated with poor prognosis compared with lack of expression of
ESR1. Furthermore, a scatter plot (Figure 5.3B) of the METABRIC expression levels of
the FGD3 -SUSD3 metagene versus ESR1 revealed that the two features were associated
in the sense that ER-negative breast cancers tended to express low levels of the FGD3 -
SUSD3 metagene, but the reverse was not necessarily true.
The poor prognosis associated with low expression of the FGD3 -SUSD3 metagene
was validated in the OsloVal data set. Figure 5.3C shows the Kaplan-Meier curves for
the FGD3 -SUSD3 metagene in the METABRIC data set (P < 2× 10−16 using log-rank
test) and the OsloVal data set (P = 0.0028 using log-rank test). In both cases, the curves
compare tumors with high and low expression of the FGD3 -SUSD3 metagene.
5.2.5 Other Breast Cancer-Specific Features
In addition to the pan-cancer attractor signatures and the FGD3 -SUSD3 metagene,
we applied the unsupervised attractor-finding algorithm on 6 independent breast cancer
data sets (see Appendix B) to obtain several breast cancer-specific attractor signatures.
Therefore, the number of potential molecular features, which were tens of thousands in
the gene expression and copy number data, was reduced to a preselected 12 features
(listed in Table 5.2). We chose these features by trial and error after several experiments,
including and removing features and evaluating the performance on the Challenge leader-
board and in cross-validation. The set of features used in the final model included: (i)
the three attractor features and the FGD3-SUSD3 metagene described above, (ii) the
chr8q24.3 amplicon attractor signature (see Section 3.7) and the chr15q26.1 genomically
co-localized attractor metagene (which we found to be the most prognostic amplicon in
the METABRIC training data set), (iii) three breast cancer-specific attractor metagenes
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Feature Gene Members Note
CIN feature As defined in Table 3.1 Pan-cancer
MES feature As defined in Table 3.1
Pan-cancer. Use condition: Patients with
early-stage tumors (no positive lymph
node and tumor size < 30 mm)
LYM feature As defined in Table 3.1
Pan-cancer. Use conditions: (1)





















































Pan-cancer (although not the top three
strongest as defined in Table 3.1)
Table 5.2: Molecular features used in the model
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(the ER metagene, the adipocyte metagene, and the HER2 metagene), and (iv) two
additional metagenes − ZMYND10 metagene and the PGR-RAI2 metagene − whose
inclusion often improved performance. Both the ZMYND10 and PGR-RAI2 metagenes
were protective (their individual CIs in all breast cancer data sets were less than 0.5).
The rationale for considering these metagenes was that we wished to include additional
protective features, and these ones were highly protective while at the same time not
positively correlated with the most protective feature, the FGD3 -SUSD3 metagene. See
Section 5.3.1 for derivation of features from these metagene features.
5.3 Building an Ensemble Prognostic Model
Building our prognostic model involved derivation and selection of relevant features, train-
ing the submodels using the derived features based on survival information, and combin-
ing predictions from the submodels to produce a robust ensemble prediction. Figure 5.4
shows block diagrams describing our final model in the Challenge. The source code of
the model is available on Sage Synapse under ID syn1417992.
5.3.1 Derivation of Features
Each metagene feature used in our model was defined by the average expression value of
each of the 10 top-ranked genes in every attractor metagene. If, however, some of these
10 genes had average mutual information with the attractor metagene − as defined in
Section 2.3 − that was less than 0.5, it was removed from consideration when deriving the
metagene feature. If a gene was profiled by multiple probes in the microarray, we selected
the probe with the highest degree of coexpression with the metagene. The selection was
done by applying the iterative attractor-finding algorithm on all the probes for the top
10 genes and selecting the top-ranked probe for each gene. The expression values of each
metagene feature were median-centered by subtracting their median value.
All the categorical variables, such as histological type or tumor grade, were bina-
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Figure 5.4: Schematic of model development. Shown are block diagrams that describe the de-
velopment stages for our final ensemble prognostic model. Building a prognostic model involves
derivation of relevant features, training submodels and making predictions, and combining pre-
dictions from each submodel. Our model derived the attractor metagenes using gene expression
data, combined them with the clinical information (through Cox regression, GBM, and KNN
techniques), and eventually blended each submodel’s prediction.
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rized by representing each category with a binary variable. In that case, missing val-
ues were assigned zero in each binary variable. For example, the categorical variable
“ER IHC status” (a variable that describes the immunochemistry status of ER) was
binarized into two binary variables: ER-positive (ER.P) and ER-negative (ER.N). ER-
positive patients were assigned [1, 0] for these two variables, ER-negative patients were
assigned [0, 1], and patients with missing ER status were uniquely assigned [0, 0]. Miss-
ing values in numerical variables were imputed by the average of the nonmissing values
across all samples.
As described in the previous section, in our model, we used three metagene features
restricted to specific subcohorts: the MES feature restricted to tumor sizes of less than
30 mm and no positive lymph nodes, the LYM feature restricted to ER-negative patients,
and the LYM feature restricted to patients with more than three positive lymph nodes.
We restricted the features by median-centering the metagene’s expression values of the
subgroup of samples which satisfy the condition using the subgroup’s median, and setting
the values of the remaining samples to zero.
5.3.2 Building Prognostic Models
A prognostic model selects particular features out of a set of derived features and combines
them using an algorithm for optimally fitting the given survival information. Our ensem-
ble model consisted of several such submodels. The choice of these models, described
below, was made on a trial and error basis depending on the occasional leaderboard
scores of other Challenge participants and our own cross-validation scores. That is, we
randomly partitioned the available samples into a training set and a validation set, trained
the model accordingly, and recorded the CI in the validation set. Specifically, we made
several submissions to the leaderboard using initial guesses about which combinations of
features would be most prognostic and observed the resulting CIs.
During the course of the Challenge, we tried several combinations of prognostic al-
gorithms (based on various statistical and machine-learning techniques), each of which
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defined a computational model that automatically selected some of the potential fea-
tures and achieved prediction of survival. We refer to these as “submodels,” which were
eventually combined into one “ensemble” model.
Cox Regression on Akaike Information Criterion
The Cox proportional hazards model relates the effect of a unit increase in a covariate
to the hazard ratio [107]. To select from derived features as covariates in the regression
model, we performed stepwise selection based on Akaike Information Criterion (AIC)
[108]. In each step, the feature was added in or removed from the model so that each step
resulted in the lowest AIC measure. The Cox-AIC model makes predictions by computing
fitted values of the given features to the regression model.
We used AIC for feature selection on molecular features and clinical features separately
to fit Cox proportional hazards models. The molecular and clinical features selected by
the Cox-AIC model applied to the METABRIC data set are given in Table 5.3. The
predictions made by the two separate models were combined by summation.
Generalized Boosted Regression Models (GBM)
GBM adopts the exponential loss function used in the AdaBoost algorithm [109] and
uses Friedman’s gradient descent algorithm, accompanied by subsampling, to improve
predictive performance and reduce computational time [110].
We trained GBMs on molecular features and clinical features separately, as we did
for the Cox-AIC models. We used only the clinical features that were selected by the
Cox-AIC model (listed in Table 5.3) as input to the GBM. We performed fivefold cross-
validation to determine the best number of trees in the model. The tree depth was set to
the number of significant explanatory variables in the Cox-AIC model (P < 0.05 based




Feature Hazards Ratio (95% CI) P value
CIN 1.465 (1.262−1.701) 5.7× 10−7
ER 1.161 (1.089−1.237) 4.3× 10−6
FGD3 -SUSD3 0.845 (0.780−0.914) 3.0× 10−5
MES: early stage 1.206 (1.071−1.359) 2× 10−3
LYM: lymph node number > 4 1.660 (1.119−2.463) 1.2× 10−2
HER2 1.077 (0.997−1.164) 6× 10−2
LYM: ER-negative 0.754 (0.563−1.010) 5.9× 10−2
PGR-RAI2 0.871 (0.751−1.012) 7× 10−2
Clinical Features
Feature Hazards Ratio (95% CI) P value
Positive lymph node numbera 1.064 (1.052−1.076) < 2× 10−16
Age 1.032 (1.026−1.038) < 2× 10−16
Tumor Size 1.012 (1.008−1.015) 6.5× 10−12
ER-negative 1.724 (1.455−2.044) 3.4× 10−10
Radiation Therapy 0.783 (0.683−0.898) 4.8× 10−4
Histological subtype: Medullary 0.334 (0.165−0.674) 2.2× 10−3
Histological subtype: Tubular 0.521 (0.305−0.889) 1.7× 10−2
Grade 3 1.200 (1.037−1.390) 1.5× 10−2
Table 5.3: Cox proportional hazards model trained on molecular and clinical features on the
basis of AIC.
K-nearest Neighbor Models (KNN)
In our model, we used a modified version of KNN model [111] for survival prediction. We
selected the features whose values defined patients’ ranking with a CI greater than 0.6 or
less than 0.4 in the training set.
When making predictions, we computed the Euclidean distance in the selected fea-
ture space between the patient with unknown survival and each deceased patient in the
training set. The top 10% of the deceased patients with smallest distances, defined as
the “nearest neighbors,” were used to make predictions. The predictions were made by
taking the weighted average of the survival times of the nearest neighbors, where the
weight of a neighbor was the reciprocal of the distance between the neighbor and the
patient with unknown survival.
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Feature Hazards Ratio (95% CI) P value
Positive lymph node number 1.064 (1.053−1.075) < 2× 10−16
Age 1.035 (1.029−1.041) < 2× 10−16
FGD3 -SUSD3 0.835 (0.788−0.886) 2.3× 10−9
CIN 1.394 (1.218−1.597) 1.6× 10−6
MES: early stage 1.212 (1.070−1.373) 0.002
LYM: ER-negative 0.714 (0.541−0.943) 0.018
Table 5.4: Cox proportional hazards models trained on empirically selected features
Combination of Cox Regression and GBM Applied on Empirically Selected
Features
By trial and error, we observed that the performance of the overall model was improved
by incorporating a submodel that included the four fundamental molecular features (CIN,
MES constrained to a tumor size less than 30 mm with no positive lymph node, LYM
constrained to ER-negative patients, and the FGD3 -SUSD3 metagene) together with
very few clinical features (i.e. the number of positive lymph nodes, and the age at
diagnosis). The selected features were used to fit a Cox regression model and a GBM,
whose predictions were combined by summation. The Cox proportional hazards model
trained on these features is given in Table 5.4.
5.3.3 Combination of Predictions
Our final model contained the submodels described above. We added the resulting pre-
dictions from Cox-AIC and GBM, as well as the reciprocal of the predicted survival time
given by the KNN model. Then we divided the predicted values by the standard devia-
tion of the values in the test data. We also did the same normalization on the predictions
derived from the empirically-selected features above. The final ensemble prediction was
the summation of these two.
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5.3.4 Combination of OS- and DS-based Predictions
Our best performance on the leaderboard was achieved when we trained our models
twice, once using OS-based survival data and again using DS-based survival data, and
then combining the two predictions. Therefore, we adopted the ensemble model depicted
in Figure 5.4. We combined these two sets of predictions by taking the weighted average
of the two. The weights were determined by maximizing the CI with OS in the training
set with a heuristic optimization technique.
5.4 Performance of the Prognostic Model in the BCC
Figure 5.5 shows the Kaplan-Meier cumulative survival curves for our final ensemble
prognostic model using the OsloVal data set (the P value derived from the log-rank test
was lower than the minimum computable one, which was 2× 10−16 using log-rank test).
This plot compares patients with “poor” and “good” survival predictions, according to
the ranking assigned by the model (which was trained on the METABRIC data set). The
good prognosis group had a 15-year survival rate of 65%, while the poor prognosis group
had a 15-year survival rate of 20%.
The corresponding CI of the final ensemble model in the OsloVal data set was 0.7562
in the Challenge. To test whether three of our features − CIN, MES, and LYM −
contributed toward increasing the CI for our model using the OsloVal data set, we eval-
uated the CIs after removing each feature separately and retraining the model on the
METABRIC data set without it. The resulting CI, after removing the CIN feature and
keeping the MES and LYM features, was 0.7526. The CI, after removing the MES feature
and keeping the CIN and LYM features, was 0.7514. The CI, after removing the LYM
feature and keeping the CIN and MES features, was 0.7488. In all cases, the CI was
lower than that of the ensemble model. These results are consistent with our hypothesis
that each of these three attractor metagenes provides information useful for breast cancer
prognosis.
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Figure 5.5: Kaplan-Meier cumulative survival curve of the final ensemble model (over a 15-
year period) on the basis of the predictions made by the final ensemble model in the OsloVal
data set. The patients were divided into equal-sized predicted survival subgroups (i.e. poor
and good) according to the ranking assigned by the final model, which was trained on the
METABRIC data set. The P value derived using the log-rank test was less than 2× 10−16.
In the Challenge, the OsloVal CI of 0.7562 significantly outperformed the model sub-
mitted by the second team (with P = 5.1 × 10−28 by Wilcoxon rank-sum test [112]),
as well as the model built based on the 70-gene risk signature used in MammaPrint
biomarker product [113]. The model also outperformed two test models built on clini-
cal covariates (with CI 0.7001 and 0.6964), showing the significant additional prognostic
values provided by the attractor signatures [103].
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Table 5.5: CIs of the CIN feature and meta-PCNA index in four breast cancer data sets.
5.5 Comparison with Random Gene Expression
Signatures
Venet et al. recently observed that randomly chosen gene expression signatures may
often be significantly associated with breast cancer outcomes [114]. To explain this phe-
nomenon, the authors introduced a specially defined proliferation signature − called
meta-PCNA − which consists of 127 genes whose expression levels were most positively
correlated with that of the proliferation marker PCNA, as determined from a gene expres-
sion data set of normal tissues. They observed that the meta-PCNA signature, although
derived from an analysis of normal tissues, was prognostic for breast cancer outcome, and
that the expression levels of many other genes were also associated with the meta-PCNA
signature to varying degrees. Thus, they explained the observed association of random
signatures with breast cancer outcome by the fact that several member genes of such
random signatures were likely to be associated with those prognostic genes.
The meta-PCNA signature is highly similar to our own mitotic CIN attractor meta-
gene. Indeed, 36 of the 127 genes in the meta-PCNA signature are among the 100
top-ranked genes of the CIN signature defined in Table 3.1 (the P value for such overlap
is 4.03× 10−53, based on Fisher’s exact test).
Therefore, both the meta-PCNA signature, which was derived from normal tissue
analysis, and the mitotic CIN attractor metagene, which was derived from a multicancer
analysis, can be used to explain the observed phenomenon that random gene expression
signatures are associated with breast cancer outcomes. To compare the mitotic CIN
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signature with the meta-PCNA signature, we evaluated the corresponding CIs for the
two breast cancer data sets (NKI and Loi) used in the meta-PCNA study [114], the
METABRIC data set using both DS- and OS-based survival data, and the OsloVal data
set. In all five cases, the CIs of the CIN feature were slightly higher than those of the
meta-PCNA signature (Table 5.5). We hypothesized that the large “mitotic” component
of the mitotic CIN signature was not exclusively cancer-associated, but was also found in
normal cells. By contrast, we hypothesized that the “chromosomal instability” component
of the mitotic CIN signature was cancer-related and may account for the observed, slightly
higher association with survival compared with the meta-PCNA signature. Furthermore,
the performance of our ensemble model with the OsloVal data set was higher than that
of the CIN feature alone. We will discuss more about cancer-specific gene members in
the mitotic CIN signature in Chapter 6.
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Chapter 6
Conclusions and Future Work
In this dissertation, a new data mining algorithm was presented to identify common
attractor molecular signatures shared across cancer types. While most gene signature-
identifying approaches have difficulty finding similarities among signatures in different
cancer types, our algorithm identified pan-cancer attractor signatures in multiple cancer
in nearly identical forms. The attractors produced by the algorithm also provided a rank-
ing of genes according to their degree of coexpression with other genes in the signature.
This information can be directly used to generate both attractor features to represent the
underlying biomolecular mechanisms for hypotheses generating and features for predictive
modeling.
In Chapter 3, 18 pan-cancer attractor signatures were presented. We hypothesized
that four of the most prominent signatures represented “bioinformatic hallmarks” of can-
cer, namely mitotic chromosomal instability (CIN), mesenchymal transition (MES), a
lymphocyte-specific immune recruitment (LYM), and tumor angiogenesis (END). While
the meaning of several signatures remains to be investigated, based on the strong corre-
lation among the genes in the signature, we believe these signatures will be re-discovered
and linked to phenotype in the future. For examples, following our publication of the 18
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pan-cancer attractor molecular signatures [39], the END signature was re-discovered in
[60] as the “common angiogenesis/endothelial cells metasignature” which were regulated
in tumor angiogenesis in multiple cancer types.
In Chapter 4, a more comprehensive investigation on the MES signature showed
clinical association in multiple cancer types. While the MES signature was associated with
tumor stage in most cancers, the threshold at which the signature was most prominent
is cancer type-specific. This realisation affects how the signature is used for prognosis
prediction. The signature was also associated with time to recurrence in GBM, and its
expression is correlated with stem cell marker CD44. These two facts were consistent with
the hypothesis that the mesenchymal transition induced cancer cells to acquire stem cell
properties, leading to resistance for therapy and a shorter recurrence time. A xenograft
study also suggested that the origin of part of the signature came from human cancer cells
instead of peritumoral stromal cells. This chapter provided an example for investigating
other pan-cancer signatures.
In Chapter 5, the features derived from top genes of the attractor signatures were
used to build predictive models for breast cancer prognosis. Based on the hypothe-
sis that the pan-cancer signatures were associated with tumor progression as well as
survival, the challenges in predictive modeling shifted from finding prognostic features
into identifying conditions for pan-cancer features in order to be prognostic. Several
breast cancer-specific attractor signatures were also derived for more accurate breast
cancer profiling. The resulting model outperformed the other submitted models in the
Sage Bionetworks-DREAM Breast Cancer Prognosis Challenge, and showed significantly
higher performance than models using only clinical information provided by the attractor
signatures.
However, we fell that the attractor finding algorithm and the pan-cancer signatures
are far from reaching their potential. There is still much work which can be built upon
the findings of this thesis. We will enumerate a few of them in the following sections.
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6.1 Building Genomic Assays for Cancer Prognosis
Using Attractor Signatures
The current practice of incorporating genomic information into cancer care focuses on
molecular subtyping, identifying general treatment for each subtype, and defining excep-
tions in subtypes and corresponding actions. However, we argue that such practices have
done a disservice to the biomedical community. The quantitative nature of genomic assays
provides more information to prognosis. We propose that the prognostic modeling pro-
cess in BCC is also applicable to other cancer types The restrictions for each pan-cancer
feature to show prognostic power were first identified. Additional cancer type-specific
metagenes can then be added for tailoring to cancer-specific predictions. The pan-cancer
signatures can serve as “building blocks” for biomarker products in multiple cancer types.
For breast cancer, although the model built in the BCC significantly outperformed
other proposed computational models, the model is not clinically applicable. Because the
model was built on data from retrospective study and contained therapy information, the
prediction made using such information was based on the assumption that all patients
received therapy under a universal treatment guideline, which was not true. To modify
the Challenge-winning model into a clinically-applicable model (or formula) for prognosis,
we envision a biomarker product using only the tumor size, number of positive lymph
nodes, the CIN, MES and LYM signatures, HER2 amplicon signatures, and the FGD3 -
SUSD3 metagene. Through the combination of both features measuring the fundamental
characteristics and features highly associated with breast cancer prognosis, we believe
such an assay will provide new perspective on integrating molecular features into cancer
prognosis.
In order to establish such a prognostic assay, it is essential to compare the performance
of the model with the biomarker products that are currently used by physicians, such
as the Oncotype DX [115], MammaPrint [3], and the Risk of Recurrence (ROR) scores
produced by PAM50 [17]. We have initiated a preliminary investigation comparing the
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prognostic performance of a combination of the attractor features and the FGD3 -SUSD3
metagene (for simplicity, we will refer to them as the “attractor panel”) with the molecular
features used in these three genomic assays. One limitation of the study was caused
by the fact that currently, most public breast cancer genomic data sets may not have
profiles of the FGD3 and SUSD3 genes. These two genes were rarely mentioned in
the previous study and, therefore, were not included in the design of early microarrays
such as Affymetrix HG U133A series. On the other hand, each genomic assay uses
different platform to obtain genomic profiles; Oncotype DX uses RT-PCR, MammaPrint
uses customized Affymetrix microarrays, and PAM50 is based on NanoString’s nCounter
Analysis System. It is difficult to reach a fair comparison without some approximation
to the prognosis made by these platform.
One alternative to the above issue is to compare only the prognostic performance of
the features instead of the formula, or the procedure, used by these assays to generate
prognosis. To achieve this, we compared the performance by training the molecular
features in randomly-selected half of the data set, and obtaining the CI for the other half.
We performed this random splitting experiment in three independent breast cancer data
sets 1,000 times each. The preliminary results showed that the prognostic performance of
the attractor panel significantly outperformed the Oncotype DX and the PAM50 features
in the ER-positive breast cancer patients. It also significantly outperformed MammaPrint
in lymph-negative patients with tumor size less than 50 mm. Furthermore, when applied
on full data sets without restricting to a specific subcohort, the proposed features also
outperformed the features in the other three assays.
These results indicate that it is promising to conduct a new study, rigorously com-
paring the prognosis estimated by the attractor panel with the real prognostic estimation
generated by these assays. Oncotype DX was also shown to be predictive for response to
chemotherapy [116]. Given that the attractor panel outperformed the features in the On-
cotype DX, it is also worth investigating whether the prognosis generated by the attractor
panel is also predictive for response to chemotherapy.
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6.2 Integrating Attractor Signatures with Additional
Information for Biological Discovery
While the attractor signatures capture the core of a coexpression pattern, understanding
cancer biology still requires the incorporation of additional information. For example,
using regulatory information could help identify possible targets for intervening biological
mechanisms underlying an attractor signature. Integrating mutation information with
the attractor signatures in a pathway analysis may also identify particular causal events,
which trigger the expression of the signature, and help re-construct the full biological
mechanism. There are also recent studies integrating mutation information with gene
expression for clustering analysis [117]. While it is difficult to integrate the categorical
mutation information with continuous gene expression for meta-feature calculation, given
enough sample size, it would be worth while to identify attractor signatures specific to a
cohort with particular mutations, such as TP53.
6.3 Comparing Attractor Signatures Identified in
Normal Tissues with Pan-Cancer Attractor
Signatures
One of the most fundamental questions regarding the pan-cancer attractor signatures yet
to be answered is: Are these signatures cancer-specific or are they also found in normal tis-
sues? To investigate this question, we need expression data sets containing large amounts
of corresponding, normal human tissues. For example, to generate a normal pan-tissue
signature, we need 200 normal human breast samples, 200 normal human colon sam-
ples, 200 normal human ovarian samples, etc. However, current gene expression profiling
technology has not yet reached a cost-effective point where such information could be
generated on a large scale. One of the largest gene expression data sets, containing a vast
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amount of normal tissues, comes from the Human Body Index study (GEO:GSE7307).
This study contains 504 normal samples from multiple human tissues, with the largest
cohort containing 58 samples from myometrium. Unfortunately, the small, single-tissue
sample size is too small even for MI evaluation. However, it will be interesting to see if
there are any attractor metagenes identified in a multi-tissue data set which may link the
gene signature to tissue types.
We applied the attractor finding algorithm on the Human Body Index data set. Not
surprisingly, many strongly coexpressed attractor metagenes were identified, given that
the expression profiles among different tissues led to strong coexpression patterns. One
of the strongest attractors was extremely similar to the MES signature. The top genes
in that attractor include COL6A3, COL1A2, LUM, COL3A1, DCN, MMP2, and even
SNAI2. However, the attractor misses several prominent genes in the MES signature,
such as THBS2, COL11A1, INHBA, FN1, and FBN1. We also observed that the samples
expressing high values of this attractor were from sex-organs, such as the myometrium,
ovary, endometrium, and cervix. The samples expressing low values of this attractor were
from highly differentiated organs such as the cerebellum, cerebral cortex, and caudate.
This observation is consistent with the hypothesis that part of the MES signature may
reflect the cell’s “stem-ness.” Therefore, we may hypothesize that there are two parts of
the MES signature − one part of the signature, found in normal cells, represents a cancer
cells’ ability to acquire stem cell property, and another part represents a later stage in the
invasion process, which may be cancer-specific. It will also be interesting to investigate
other normal tissue signatures and identify their relationships with tissue types.
Another data set that contains the most normal samples from the same tissue is
TCGA BRCA data set. There are 104 matched normal breast samples, which means
each of them corresponds to a cancer sample from the same patient. Using these 104
samples, although still small for attractor finding, could help generate an approximation
of the attractor signatures in normal breast tissue. We can also compare those signatures
with the attractor signatures identified in breast cancer data sets.
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We found an attractor which is very similar to the mitotic CIN signature, whose
top genes include NUSAP1, FOXM1, RRM2, TOP2A, TPX2, and even MKI67 (a.k.a.
Ki-67 ), which has been broadly used as a proliferation marker for breast cancer prog-
nosis. However, this attractor misses several key mitotic genes in the signature, such
as CENPA, MCM10, and AURKA. We suspect these genes may play important roles in
tumor progression.
Such comparisons between signatures identified in tumors and those in normal tissues
provide insight into the underlying cancer biology, and should be further studied in a
large-scale, systematic manner. While we are currently limited by the lack of large-scale
gene expression profiles of normal tissues, we expect the cost of such technologies will
go down, enabling the creation of more and more normal-tissue data sets. At that time,
more comprehensive study on these signatures will be possible.
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Estimate Normalized MI Between Two Continuous
Variables
Assuming that the continuous expression levels of two genes Gi and Gj are governed by
a joint probability density pij with corresponding marginal pi and pj, the mutual infor-
mation MI(Gi, Gj) is defined as the expected value of log
pij
pipj
. The MI is a non-negative
quantity representing the information that each one of the variables provides about the
other. The pairwise mutual information has successfully been used as a general measure
of the correlation between two random variables. We compute mutual information with
a spline-based estimator [118] using six bins in each dimension. This method divides the
observation space into equally spaced bins and blurs the boundaries between the bins
with spline basis functions using third-order B-splines. We further normalize the esti-
mated mutual information by dividing by the maximum of the estimated MI(Gi, Gi) and
MI(Gj, Gj), so the maximum possible value of MI(Gi, Gj) is 1.
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Appendix B
Data Sets and Pre-processing
B.1 Data Sets Used in This Dissertation
Data Sets of 12 Cancer Types From TCGA Pan-Cancer Project
The data platform for each cancer type and its corresponding Synapse ID is given below.
mRNA Protein miRNA DNA Methylation
Platform
Reverse Phase Protein Infinium
Illumina HiSeq Lysate Microarray Illumina HiSeq HumanMethylation27
(RPPA) BeadChip
Cancer Type Synapse ID
BLCA syn1571504 syn1681048 syn1571494 syn1889358*
BRCA syn417812 syn1571267 syn395575 syn411485
COAD syn1446197 syn416772 syn464211 syn411993
GBM syn1446214 syn416777 NA syn412284
HNSC syn1571420 syn1571409 syn1571411 syn1889356*
KIRC syn417925 syn416783 syn395617 syn412701
LAML syn1681084 NA syn1571533 syn1571536
LUAD syn1571468 syn1571446 syn1571453 syn1571458
LUSC syn418033 syn1367036 syn395691 syn415758
OV syn1446264 syn416789 syn1356544 syn415945
READ syn1446276 syn416795 syn464222 syn416194
UCEC syn1446289 syn416800 syn395720 syn416204
* The data sets were extracted from HumanMethylation450 BeadChip.
Six Gene Expression Data Sets from 3 Cancer Types
As used to generate Figure 2.2 of consensus clustering , Figure 2.3, and the comparison
with other unsupervised methods in Section 2.6.
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Data Set Source Cancer Type Platform
Wang Breast GEO:GSE2034 Breast Affymetrix HG-U133A 2.0
TCGA BRCA TCGA Breast Agilent G4502A
Jorissen Colon GEO:GSE14333 Colon Affymetrix HG-U133Plus 2.0
TCGA COAD TCGA Colon Agilent G4502A
Tothill Ovarian GEO:GSE9891 Ovarian Affymetrix HG-U133Plus 2.0
TCGA OV TCGA Ovarian Affymetrix HG-U133A
Data sets for MES signature investigation in Chapter 4
Data Set Source Cancer Type Platform
TCGA GBM TCGA Glioblastoma Affymetrix HG-U133A
Rembrandt Glioma REMBRANDT Glioma Affymetrix HG-U133Plus 2.0
Schutz Breast GEO:GSE3893 Breast Affymetrix HG-U133A, Plus 2.0
Data sets for BCC
Data Set Synapse ID
METABRIC syn1688369
OsloVal syn1688370
B.2 Pre-processing of Data Sets
B.2.1 Pre-processing of Gene Expression Microarray Data Sets
All references to gene expression levels, including average values and numbers on scatter-
plot axes, are assumed to be log2-normalized as provided to us. All the affymetrix
microarray data sets were normalized using the Robust Multi-array Average (RMA).
Data sets from other platforms were normalized as provided by the data provider.
B.2.2 Pre-processing of RNASeq and miRNASeq Data Sets
For each RNA sequencing and miRNA sequencing data set, the mRNAs or miRNAs
in which more than 50% of the samples have zero counts were removed from the data
set. All the zero counts and missing values in the data sets were imputed using the k-
nearest neighbors algorithm as implemented in the impute package in Bioconductor. The
log2 transformed counts were then normalized using the quantile normalization methods
implemented in Bioconductor’s limma package. We further summarized the miRNA
expression values by taking the average expression values of the miRNAs with the same
gene family names.
B.2.3 Pre-processing of DNA Methylation and RPPA Data Sets
The missing values in the protein and DNA methylation data sets were also imputed
using the k-nearest neighbors algorithm in the impute package. For bladder and head
and neck methylation data sets, for which only the Humanmethylation450 platform were
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provided, we extracted the 23,380 overlapping probes between the Humanmethylation27
and HumanMethylation450 platforms as new data sets for analysis.
B.2.4 Clustering Attractors and Creating Consensus Molecular
Signatures in Pancan 12 Data Sets
After obtaining the converged attractors in each data set, we performed a clustering al-
gorithm to identify extremely similar attractors across different cancer types as described
in Chapter 2. We used the top features − mRNAs, miRNAs, proteins, or methylation
probes − in each attractor as a feature set, then performed hierarchical clustering on the
feature sets across the cancer types, using the number of overlapping features as the sim-
ilarity measure. The number of top features used to represent the attractor was chosen
according to the distribution of the features’ weights in the attractors.
For the mRNA attractors, we used the top 20 features to create such feature sets. For
the methylation attractors, we used top 50 features for clustering. For the miRNA and
protein attractors, we used the top five features for clustering. We removed methylation
attractor clusters containing sites exclusively on the X or Y chromosome, because we
found that their values were gender-dependent. If an attractor cluster did not contain
any gene that found in at least six cancer types, it was removed from consideration.
To account for the fact that some of the twelve data sets may not contain sufficient
heterogeneous samples for showing each pan-cancer biomolecular event, the decision of
selecting a signature was based on its clear presence in at least half of the cancer types,
i.e., six different cancer types. We thus created a consensus molecular signature from each
attractor cluster as follows: We first identified, for each cluster, six significant attractors
by calculating the sum of the similarity measures (as defined by the number of overlapping
features) between each attractor and all the other attractors, ranking the attractors using
this quantity, and selecting the six top-ranked attractors. If an attractor cluster contained
less than six attractors, it was removed from consideration. We then calculated the
average MI for each feature across the six attractors and ranked the features accordingly




Table C.1: Top 100 genes of the mitotic CIN signature
Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol
1 TPX2 26 MELK 51 CEP55 76 C15orf42
2 KIF4A 27 NEK2 52 CDC6 77 KPNA2
3 KIFC1 28 AURKB 53 BIRC5 78 ZWINT
4 NCAPG 29 PRC1 54 CDK1 79 FAM72B
5 BUB1 30 ASPM 55 ARHGAP11A 80 ESCO2
6 NCAPH 31 KIF20A 56 RAD54L 81 PLK4
7 CDCA5 32 EXO1 57 STIL 82 ASF1B
8 KIF2C 33 CDC20 58 CDC45 83 ECT2
9 PLK1 34 MYBL2 59 DTL 84 ESPL1
10 CENPA 35 RACGAP1 60 CDC25C 85 LMNB1
11 TOP2A 36 RRM2 61 DEPDC1B 86 SPAG5
12 HJURP 37 SGOL1 62 EPR1 87 FAM64A
13 BUB1B 38 DEPDC1 63 CCNB1 88 PTTG1
14 KIF23 39 ORC1L 64 ERCC6L 89 CASC5
15 FOXM1 40 TROAP 65 MKI67 90 CDKN3
16 MCM10 41 UBE2C 66 KIF18A 91 UHRF1
17 KIF18B 42 TTK 67 SPC25 92 SHCBP1
18 CCNA2 43 SKA3 68 GSG2 93 OIP5
19 GTSE1 44 AURKA 69 CDCA3 94 PBK
20 CKAP2L 45 KIF15 70 CENPI 95 SPC24
21 CCNB2 46 NUSAP1 71 CENPE 96 ORC6L
22 DLGAP5 47 NUF2 72 CDCA2 97 HMMR
23 KIF11 48 SKA1 73 FANCI 98 FAM54A
24 CDCA8 49 CENPF 74 POLQ 99 NEIL3
25 KIF14 50 NDC80 75 RAD51 100 FAM72D
Table C.2: Top 100 genes of the MES signature
Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol
1 COL3A1 26 CTSK 51 OLFML1 76 MFRP
2 COL5A2 27 PRRX1 52 MXRA5 77 ZEB1
3 COL1A2 28 ADAMTS12 53 CTHRC1 78 LRRC32
Continued on next page...
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Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol
4 THBS2 29 ANGPTL2 54 PCOLCE 79 LOX
5 COL5A1 30 BGN 55 ACTA2 80 BICC1
6 VCAN 31 SFRP2 56 GREM1 81 COL15A1
7 COL6A3 32 FNDC1 57 DCN 82 TGFB3
8 SPARC 33 ISLR 58 CALD1 83 ITGBL1
9 AEBP1 34 COL10A1 59 MSRB3 84 MRC2
10 FBN1 35 CRISPLD2 60 NTM 85 P4HA3
11 POSTN 36 COL8A1 61 COL12A1 86 CD248
12 FAP 37 BNC2 62 PODN 87 ZNF521
13 MMP2 38 LUM 63 HEPH 88 SPON1
14 COL1A1 39 ANTXR1 64 SSC5D 89 PMP22
15 PDGFRB 40 ASPN 65 INHBA 90 OMD
16 LRRC15 41 THY1 66 FIBIN 91 SFRP4
17 ADAMTS2 42 COL6A1 67 ECM2 92 COL5A3
18 ITGA11 43 NID2 68 TAGLN 93 SERPINF1
19 ADAM12 44 COL11A1 69 HTRA3 94 FILIP1L
20 OLFML2B 45 FN1 70 FSTL1 95 KIAA1462
21 COL6A2 46 LAMA4 71 ZNF469 96 LOXL2
22 EMILIN1 47 DACT1 72 SGCD 97 COL8A2
23 TIMP2 48 SULF1 73 MXRA8 98 ZEB2
24 CDH11 49 CCDC80 74 WISP1 99 TMEM119
25 GLT8D2 50 GPR124 75 RASGRF2 100 TSHZ3
Table C.3: Top 168 genes with consensus MI > 0.5 in the LYM signature
Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol
1 SASH3 43 CD48 85 P2RY10 127 LY86
2 CD53 44 APBB1IP 86 CD300LF 128 HLA-DMB
3 NCKAP1L 45 C1QC 87 HLA-DRA 129 KIAA0748
4 LCP2 46 CD3E 88 NCF1 130 IL16
5 IL10RA 47 GIMAP5 89 LILRB4 131 CSF2RB
6 PTPRC 48 RASAL3 90 FCGR1A 132 CD3D
7 EVI2B 49 SPN 91 P2RY13 133 WIPF1
8 BIN2 50 C3AR1 92 SLC7A7 134 SIGLEC7
9 WAS 51 GPR65 93 C1orf162 135 DOK3
10 HAVCR2 52 FGL2 94 C17orf87 136 SIRPG
11 MYO1F 53 TAGAP 95 CXorf21 137 TIGIT
12 CCR5 54 MNDA 96 CYTIP 138 RHOH
13 SPI1 55 EVI2A 97 NFAM1 139 ACAP1
14 SELPLG 56 CSF1R 98 CORO1A 140 CD247
15 CYTH4 57 DOCK2 99 GIMAP6 141 SLA2
16 SLA 58 IRF8 100 LST1 142 UBASH3A
17 LAIR1 59 SIGLEC10 101 ARHGAP30 143 NCF4
18 LAPTM5 60 SAMSN1 102 RCSD1 144 GAB3
19 PLEK 61 IKZF1 103 IL2RG 145 CD52
20 BTK 62 HLA-DPB1 104 PTPN7 146 CTSS
21 FERMT3 63 CD86 105 FPR3 147 ITGAX
22 CYBB 64 SLAMF6 106 CD14 148 CCL5
23 ITGAL 65 TFEC 107 FYB 149 SIT1
24 CD4 66 CD84 108 GIMAP1 150 PARVG
25 ARHGAP9 67 IGSF6 109 IL2RB 151 PYHIN1
Continued on next page...
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Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol
26 LILRB1 68 SLCO2B1 110 SH2D1A 152 NKG7
27 SLAMF8 69 LILRB2 111 TNFSF13B 153 CD300A
28 MPEG1 70 HLA-DPA1 112 TRAF3IP3 154 LOC100233209
29 C1QA 71 LAT2 113 CMKLR1 155 GZMK
30 CD37 72 TNFAIP8L2 114 CXCR6 156 AOAH
31 ABI3 73 ARHGAP15 115 CCR2 157 CD180
32 MS4A6A 74 FAM78A 116 GIMAP7 158 MS4A7
33 ITGB2 75 TLR8 117 GMFG 159 GVIN1
34 FCER1G 76 ITK 118 SRGN 160 CD33
35 DOK2 77 FCGR3A 119 CCR1 161 FGD2
36 SNX20 78 HCST 120 LYZ 162 LY9
37 C1QB 79 IL12RB1 121 TLR7 163 MS4A4A
38 GIMAP4 80 LRRC25 122 IFI30 164 FMNL1
39 CD2 81 PIK3R5 123 SLAMF1 165 FGR
40 AIF1 82 CXCR3 124 FCGR1B 166 TRPV2
41 IL21R 83 RNASE6 125 LPXN 167 HCK
42 TYROBP 84 TNFRSF1B 126 PTPN22 168 WDFY4
Table C.4: Top 27 methylation sites with consensus MI > 0.5 in the M− signature
Rank Methylation Site Rank Methylation Site Rank Methylation Site
1 BIN2 12 50003941 10 ACAP1 17 7180947 19 ICAM3 19 10311022
2 PTPRCAP 11 66961771 11 SHROOM1 5 132189766 20 CARD8 19 53444802
3 TNFAIP8L2 1 149395922 12 OSM 22 28991949 21 MPHOSPH9 12 122273780
4 IGFLR1 19 40925164 13 NCKAP1L 12 53177901 22 TBC1D10C 11 66928161
5 FAM113B 12 45896487 14 CD79B 17 59363339 23 CTSZ 20 57016289
6 CD6 11 60495754 15 PLD4 14 104462063 24 C16orf54 16 29664824
7 KLHL6 3 184755939 16 CD6 11 60495748 25 PPP1R16B 20 36867217
8 PTPN7 1 200396189 17 CD101 1 117345939 26 CEBPE 14 22659259
9 FAM78A 9 133141340 18 FAM113B 12 45895624 27 TRAF1 9 122728536
Table C.5: Top 27 genes with consensus MI > 0.5 in the END signature
Rank Gene Symbol Rank Gene Symbol Rank Gene Symbol
1 CDH5 10 MYCT1 19 ACVRL1
2 ROBO4 11 TIE1 20 ECSCR
3 CXorf36 12 S1PR1 21 VWF
4 CD34 13 ESAM 22 KDR
5 CLEC14A 14 PCDH12 23 EMCN
6 ARHGEF15 15 RHOJ 24 PTPRB
7 CD93 16 BCL6B 25 NOTCH4
8 LDB2 17 TEK 26 ERG
9 ELTD1 18 GPR116 27 PECAM1
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Table C.6: Association of MES signature with tumor stage








1 COL11A1 6.497 V COL11A1 3.348 V SPP1 2.862
2 COL10A1 4.072 V COL10A1 2.182 V COL10A1 2.759 V
3 MFAP5 3.733 TIMP3 2.034 COL11A1 2.174 V
4 LRRC15 3.61 V POSTN 2.008 V SFRP2 2.11 V
5 INHBA 3.442 V THBS2 1.993 V GAS1 2.079
6 FBN1 3.428 V EPYC 1.936 ASPN 2.051 V
7 SULF1 3.353 V COL5A2 1.892 V GREM1 1.9 V
8 GREM1 3.351 V MMP11 1.876 CDKN2B 1.886
9 COL5A2 3.222 V ASPN 1.875 V PLN 1.852
10 LOX 3.222 V LUM 1.867 V VIP 1.831
11 COL5A1 3.077 V VCAN 1.825 V CYP1B1 1.825
12 THBS2 2.991 V FAP 1.8 V THBS2 1.819 V
13 LAMB1 2.973 COMP 1.768 COL8A1 1.798 V
14 FAP 2.96 V GAS1 1.762 SULF1 1.792 V
15 SPOCK1 2.908 INHBA 1.752 V POSTN 1.784 V
16 PLXNC1 2.899 PTGIS 1.728 MAB21L2 1.783
17 PLAU 2.89 COL5A1 1.728 V TAC1 1.758
18 LY96 2.882 THY1 1.718 V HOPX 1.757
19 MMP1 2.832 CTSK 1.696 V TNFAIP6 1.756
20 ADAM12 2.829 V LRRC15 1.692 V AKAP12 1.744
21 AEBP1 2.812 V MMP2 1.686 V TAGLN 1.735 V
22 NID2 2.806 V AEBP1 1.662 V GULP1 1.725
23 COL6A2 2.773 V PCP4 1.654 FNDC1 1.721 V
24 DACT1 2.74 V SFRP4 1.646 V SPOCK1 1.71
25 ASPN 2.729 V MAL 1.638 OLR1 1.691
26 VCAN 2.7 V NNMT 1.615 NTM 1.686 V
27 RGS4 2.689 COL3A1 1.608 V MSRB3 1.674 V
28 HLA-
DRA
2.633 CDH6 1.595 HMCN1 1.668
29 BGN 2.626 V LOX 1.592 V ADAM12 1.665 V
30 TNFAIP6 2.61 COL1A1 1.588 V CXCL5 1.661
31 NOX4 2.606 TAGLN 1.578 V PCDH7 1.66
32 NID1 2.591 FBN1 1.575 V CTHRC1 1.655 V
33 CDH11 2.588 V CYR61 1.572 SYNPO2 1.652
34 MMP13 2.539 PDGFD 1.569 DSG3 1.644
35 OLFML2B 2.534 V PCOLCE 1.568 V TNS1 1.643
36 LAMA4 2.515 V NLGN4X 1.564 SFRP4 1.639 V
37 FERMT2 2.505 NR2F1 1.558 TNC 1.637
38 LOXL2 2.452 V CRYAB 1.55 MYL9 1.635
39 EDNRA 2.446 FABP4 1.55 CALB1 1.631
40 ZEB1 2.439 V FGF18 1.549 FAP 1.63 V
41 MMP2 2.411 V ALDH1A2 1.544 TIMP3 1.612
42 AHNAK2 2.404 DCN 1.542 V FN1 1.6 V
43 HLA-
DMA
2.401 FRZB 1.536 MGP 1.6
44 COL3A1 2.394 V EDNRA 1.523 LOX 1.589 V
45 ISLR 2.392 V PDGFRL 1.521 CD109 1.587
46 CTSK 2.388 V PLAU 1.52 INHBA 1.569 V
47 MS4A4A 2.377 PCSK5 1.515 ANTXR1 1.559 V
48 WIPF1 2.375 MFAP4 1.512 IBSP 1.558
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49 COL1A1 2.374 V LRRC17 1.51 VGLL3 1.557
50 SNAI2 2.369 ACTA2 1.505 V KAL1 1.553
51 ITGBL1 2.368 V NUAK1 1.503 NEXN 1.546
52 DNM3 2.353 AQP1 1.502 FRMD6 1.54
53 KCTD12 2.348 NBL1 1.496 CCDC80 1.539 V
54 HLA-
DPA1
2.347 ADH1B 1.489 DKK2 1.535
55 ZEB2 2.346 V CXCL14 1.489 IGFBP5 1.535
56 SERPINF1 2.345 V PDLIM3 1.487 AOC3 1.525
57 SPON1 2.329 V SRPX 1.487 PLA2G16 1.523
58 DCN 2.328 V CTGF 1.47 GPNMB 1.521
59 HTRA1 2.314 CRISPLD2 1.466 V ITGBL1 1.52 V
60 NNMT 2.305 KIAA1199 1.462 MFAP5 1.52
61 GBP1 2.28 SLIT2 1.452 AHNAK2 1.52
62 ROBO1 2.275 MFAP5 1.45 EFEMP1 1.518
63 GPX7 2.271 BGN 1.449 V ACTG2 1.515
64 RECK 2.267 FBLN1 1.449 PPAPDC1A 1.514
65 TCF4 2.26 SERPINF1 1.448 V CCL18 1.511
66 DSE 2.258 APOA1 1.443 ISLR 1.506 V
67 MMP11 2.243 ERBB4 1.442 DES 1.502
68 COL8A2 2.234 V FN1 1.44 V SORBS1 1.501
69 C1QB 2.23 C1QTNF3 1.436 VCAN 1.5 V
70 SRPX2 2.225 MFAP2 1.432 COL1A1 1.498 V
71 CLEC7A 2.224 TMEM158 1.429 COL1A2 1.494 V
72 QKI 2.222 IGFBP2 1.429 SLC2A3 1.494
73 SAMSN1 2.216 RHOBTB3 1.427 BGN 1.49 V
74 HLA-
DPB1
2.213 EFEMP1 1.425 MMP11 1.487
75 COL14A1 2.204 GUCY1A3 1.423 TPM2 1.483
76 POSTN 2.185 V PDGFRA 1.421 RAB31 1.479
77 CTGF 2.182 FST 1.42 TSPAN2 1.477
78 OLFML1 2.18 V PTRF 1.419 CRISPLD1 1.473
79 ZFPM2 2.177 SLIT3 1.419 COMP 1.469
80 ADCY7 2.175 APBB2 1.417 COL3A1 1.467 V
81 COL15A1 2.17 V C7orf10 1.417 TREM1 1.466
82 COL1A2 2.16 V ETV1 1.415 CYBRD1 1.465
83 LOXL1 2.154 SPOCK1 1.414 WWTR1 1.464
84 MXRA5 2.152 V WASF1 1.413 CNN1 1.464
85 DPYD 2.145 TWIST1 1.413 SHISA2 1.464
86 HEPH 2.14 V MYH10 1.412 MITF 1.461
87 TGFB1I1 2.135 SPARC 1.411 V EREG 1.461
88 HLA-
DRB1
2.123 MXRA8 1.411 V MEIS2 1.461
89 COL6A3 2.106 V UPK3B 1.406 EPYC 1.458
90 FSTL1 2.104 V TCF4 1.404 FBN1 1.458 V
91 SGCD 2.101 V ITGBL1 1.397 V COLEC12 1.457
92 LCP2 2.095 CDH11 1.393 V BCAT1 1.456
93 MAF 2.093 ISLR 1.392 V TIMP2 1.453 V
94 SPARC 2.089 V AKAP12 1.391 C5AR1 1.453
95 ACSL4 2.083 SOX9 1.387 BHLHE41 1.45
96 SLC2A3 2.082 ADAM12 1.385 V CALD1 1.449 V
97 IGL@ 2.079 PLVAP 1.383 SCG2 1.448
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98 HEG1 2.072 NCAM1 1.379 COL5A2 1.445 V
99 MS4A6A 2.071 SOX11 1.378 STON1 1.442
100 RGS2 2.066 SLC16A3 1.377 IFIT1 1.442
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